<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?covid-19-tdm?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
    <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
    <journal-title-group>
      <journal-title>Scientific Reports</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2045-2322</issn>
    <publisher>
      <publisher-name>Nature Publishing Group UK</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9719543</article-id>
    <article-id pub-id-type="pmid">36463386</article-id>
    <article-id pub-id-type="publisher-id">25412</article-id>
    <article-id pub-id-type="doi">10.1038/s41598-022-25412-x</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>PHEVIR: an artificial intelligence algorithm that predicts the molecular role of pathogens in complex human diseases</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Zhou</surname>
          <given-names>Hongyi</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Astore</surname>
          <given-names>Courtney</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Skolnick</surname>
          <given-names>Jeffrey</given-names>
        </name>
        <address>
          <email>skolnick@gatech.edu</email>
        </address>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.213917.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2097 4943</institution-id><institution>Center for the Study of Systems Biology, School of Biological Sciences, </institution><institution>Georgia Institute of Technology, </institution></institution-wrap>950 Atlantic Drive, N.W., Atlanta, GA 30332 USA </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>3</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>3</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>20889</elocation-id>
    <history>
      <date date-type="received">
        <day>15</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>29</day>
        <month>11</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Infectious diseases are known to cause a wide variety of post-infection complications. However, it’s been challenging to identify which diseases are most associated with a given pathogen infection. Using the recently developed LeMeDISCO approach that predicts comorbid diseases associated with a given set of putative mode of action (MOA) proteins and pathogen-human protein interactomes, we developed PHEVIR, an algorithm which predicts the corresponding human disease comorbidities of 312 viruses and 57 bacteria. These predictions provide an understanding of the molecular bases of complications and means of identifying appropriate drug targets to treat them. As an illustration of its power, PHEVIR is applied to identify putative driver pathogens and corresponding human MOA proteins for Type 2 diabetes, atherosclerosis, Alzheimer’s disease, and inflammatory bowel disease. Additionally, we explore the origins of the oncogenicity/oncolyticity of certain pathogens and the relationship between heart disease and influenza. The full <bold>PHEVIR</bold> database is available at <ext-link ext-link-type="uri" xlink:href="https://sites.gatech.edu/cssb/phevir/">https://sites.gatech.edu/cssb/phevir/</ext-link>.</p>
    </abstract>
    <kwd-group kwd-group-type="npg-subject">
      <title>Subject terms</title>
      <kwd>Computational biology and bioinformatics</kwd>
      <kwd>Infectious diseases</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id>
            <institution>National Institutes of Health</institution>
          </institution-wrap>
        </funding-source>
        <award-id>R35GM118039</award-id>
        <award-id>R35GM118039</award-id>
        <award-id>R35GM118039</award-id>
        <principal-award-recipient>
          <name>
            <surname>Zhou</surname>
            <given-names>Hongyi</given-names>
          </name>
          <name>
            <surname>Astore</surname>
            <given-names>Courtney</given-names>
          </name>
          <name>
            <surname>Skolnick</surname>
            <given-names>Jeffrey</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Introduction</title>
    <p id="Par2">Infectious diseases have been a source of widespread, fatal outcomes throughout history<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. As typified by COVID-19, pandemics in recent decades have become more frequent and deadly<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Yet, host–pathogen interactions are poorly characterized, and how they result in post-infection complications are not well-understood<sup><xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR7">7</xref></sup>. Host–pathogen interactome data provides an opportunity to assess putative diseases that can be at least partly attributed to a given set of host proteins that interact with a given pathogen. Characterizing such pathogen-disease associations can yield new areas of research and opportunities to develop targeted preventatives and therapeutics to not only treat the pathogenic infection itself but also prevent its potential downstream disease consequences<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
    <p id="Par3">The COVID-19 pandemic has graphically illustrated numerous associations between SARS-CoV-2 and post-infection complications, such as loss of smell or unusual neurological symptoms<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. Thus, it is obvious that infectious diseases can impact human health well beyond the initial virus infection. Although there is evidence that individuals with some common complex diseases are more susceptible to certain infectious diseases<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, the contrary hasn’t been widely explored. That is, there has been limited research undergone to assess the association between viral or bacterial infections and the subsequent development of common complex diseases such as Type 2 diabetes, atherosclerosis, Alzheimer’s disease, and inflammatory bowel disease (IBD). For example, some cases of Alzheimer’s disease could be seeded by pathogen infection<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Furthermore, little is known about the post-infection complications associated with prevalent infectious diseases such as Influenza A and B, <italic>E. coli</italic>, Herpes simplex 1 and 2, salmonella, Epstein-Barr Virus (EBV) and clostridium difficile. For example, EBV infection increases the risk of developing autoimmune diseases such as IBD, Type 1 diabetes, and celiac disease<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. More generally, perhaps pathogen infections play a greater role in causing complex human diseases than was previously appreciated.</p>
    <p id="Par4">Research has provided significant evidence that viruses and bacteria have oncogenic (cancer causing) and oncolytic (cancer treating) potential<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. Indeed, eleven pathogens are now classified as carcinogenic according to the International Agency for Research on Cancer (IARC)<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Currently, approximately 12% of cancers have a known oncovirus association<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Both DNA and RNA viruses can contribute to cancer. For example, Epstein-Barr virus, a dsDNA virus, and human T-cell lymphotropic virus-1 (HTLV-1), an ssRNA-RT virus, are both implicated in some cancers. Some strains of human papillomavirus (HPV) cause cervical cancer<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. There has also been speculation that SARS-CoV-2 might be an oncovirus<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Other pathogens could help in treating rather than causing cancers<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. For examples, H5N1 influenza can induce cellular apoptosis<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>; measles viruses are oncolytic<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, and herpes simplex virus 1(HSV-1) kills cancer cells<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. However, despite such clear associations, it is unknown whether other pathogens also have a significant oncogenic/oncolytic potential. The problem is that oncogenic viruses might not give rise to cancers until a decade or longer following initial infection. As such, establishing the clinical connection between viral infection and the subsequent development of cancer is challenging.</p>
    <p id="Par5">To enhance the understanding of the mode of action (MOA) proteins driving the down-stream consequences associated with pathogen infection, we have developed the PHEVIR algorithm: disease comorbidities Predicted using Human–pathogEn interactomes for VIRulence. Here, we employ LeMeDISCO<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, a recently developed tool that predicts on a proteomic scale human disease comorbidities, comorbidity enriched human MOA proteins and pathways given a pathogenic gene-human interactome set. At present, the pathogen-human interactome is provided by the HPIDB database<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> but in practice any set of human–pathogen protein–protein interactions may be used. This work exploits the proteomic scale prediction of human disease MOA proteins for diseases identified by the artificial intelligence (AI) based method MEDICASCY<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. The results of this analysis for 312 viruses and 57 bacteria are compiled in the PHEVIRdb whose goal is to guide and encourage research on human diseases that may be at least partly driven by pathogen infection. It is possible that it may take years post-infection for such complications to occur, or on the contrary, the predicted comorbidities explain how a preexisting disease might make one more susceptible to the particular comorbid infectious disease.</p>
  </sec>
  <sec id="Sec2">
    <title>Results</title>
    <sec id="Sec3">
      <title>Overview</title>
      <p id="Par6">The PHEVIR algorithm works as follows: Previously we employed the LeMeDISCO<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> algorithm to predict disease co-morbidities based on a common set of mode of action (MOA) proteins. We assert that if a viral or bacterial protein interacts with these MOA proteins, it helps cause the corresponding comorbid diseases. The precision and recall rate of LeMeDISCO co-morbidity prediction on a large set of clinical observation data (~ 200,000 pairs of diseases) are 77.2 and 37.1%, respectively. On a variety of consensus datasets, in comparison to other molecular methods<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>, LeMeDISCO has an order of magnitude larger recall rate with similar precision<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. For pathogen-cancer associated (either oncogenic or oncolytic) virus prediction, on a set of 13 viruses including 9 known oncogenic viruses, the recall rate is 66.7% with a precision of 100%<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. We then examine the overall network of pathogen-diseases and focused our analysis on penetrant disease groups. Subsequently, pathogen-cancer and heart disease-flu relationships were examined in detail. For many of our predictions, we found literature evidence to support the predictions.
</p>
    </sec>
    <sec id="Sec4">
      <title>Bacterial and viral induced human disease networks</title>
      <p id="Par7">A total of 39,393 significant pathogen-disease connections were identified (q-value &lt; 0.05), of which 32,694 were virus—disease connections and 6699 were bacteria—disease connections. Of 3608 human diseases that might partially arise due to pathogen infections, 3285 unique diseases have at least one strong viral comorbidity. Similarly, 2405 unique diseases have at least one significant bacterial comorbidity. The top five viruses most connected to human diseases were Molluscum contagiosum virus subtype 1 that is comorbid to 1381 human diseases, Influenza A virus (strain A/Puerto Rico/8/1934 H1N1) that is comorbid to 1183 human diseases, Rubella virus (strain RA27/3 vaccine) that is comorbid to 1183 human diseases, Influenza A virus (strain A/Wilson-Smith/1933 H1N1) that is comorbid to 1137 human diseases, and Human immunodeficiency virus type 1 group M subtype B (isolate HXB2) that is comorbid to 1137 human diseases. The top five most connected bacteria in the network were <italic>Helicobacter pylori</italic> (strain ATCC 700392/26695) that is comorbid to 1080 human diseases, <italic>Yersinia pestis</italic> that is comorbid to 855 human diseases, <italic>Staphylococcus aureus</italic> that is comorbid to 578 human diseases, Streptococcus pyogenes serotype M1 that is comorbid to 428 human diseases, and <italic>Mycoplasma pneumoniae</italic> strain ATCC 29342/M129) that is comorbid to 406 human diseases. These results indicate that some pathogens are associated with up to one third of the diseases considered.
</p>
    </sec>
    <sec id="Sec5">
      <title>Penetrant disease groups across pathogens</title>
      <p id="Par8">Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> provide the numbers of comorbidities and their fractions in total pathogen-comorbidities for each ICD-10 main classification. The top three disease groups/classes with the greatest numbers of comorbid diseases to viruses were Neoplasms; Diseases of the eye and adnexa; and Diseases of the nervous system. The top three disease groups with the greatest numbers of comorbid diseases to bacteria were Certain infectious and parasitic diseases, Neoplasms and Diseases of the eye and adnexa. Apparently, the group of Certain infectious and parasitic diseases has the largest overall relative risk (RR, see Eq. <xref rid="Equ1" ref-type="">1</xref> for definition) (1.22 with a <italic>p</italic> value of 6.46e−04 for viruses and 2.94 with a <italic>p</italic> value of 1.41e−113 for bacteria) that is consistent with its definition. The other frequent human diseases that are comorbid to both viruses and bacteria were Neoplasms. Both have a RR greater than 1 (RR = 1.54 with a <italic>p</italic> value of 1.90e−32 for viruses, and RR = 1.25 with a <italic>p</italic> value of 1.10e−06 for bacteria) compared to background causes of the diseases (see Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). This association will be further addressed below. Another predicted high frequent comorbid disease group are Diseases of the eye and adnexa. However, it is not significantly risker than the background (RR = 1.001 with a <italic>p</italic> value of 0.98 for viruses and 1.06 with a <italic>p</italic> value of 0.33 for bacteria). Viral infections may cause irreversible neurological damage (RR = 1.12, <italic>p</italic> value = 0.06 for Diseases of the nervous system), possibly due to some of them being able to penetrate the blood brain barrier following an increased inflammatory response. This may lead to oxidative stress and dysregulation in producing sufficient energy<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. It has also been speculated that viruses might contribute to or cause autoimmune diseases. Such viruses include Influenza A virus, Coxsackie B virus, rotavirus and herpes viruses<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Thus, assessing viral-induced autoimmunity is critical to preventing post-infection downstream complications.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comorbidities of 20 ICD-10 main classifications for viruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ICD-10_main_classification</th><th align="left">Number of comorbidities</th><th align="left">Fraction of comorbidities</th><th align="left">Relative risk<sup>a</sup></th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Neoplasms</td><td char="." align="char">8089</td><td char="." align="char">0.247415</td><td char="." align="char">1.53645</td><td align="left">1.90E-32</td></tr><tr><td align="left">Diseases of the eye and adnexa</td><td char="." align="char">4952</td><td char="." align="char">0.151465</td><td char="." align="char">1.00089</td><td align="left">0.983</td></tr><tr><td align="left">Diseases of the nervous system</td><td char="." align="char">4581</td><td char="." align="char">0.140117</td><td char="." align="char">1.12094</td><td align="left">0.062</td></tr><tr><td align="left">Certain infectious and parasitic diseases</td><td char="." align="char">3756</td><td char="." align="char">0.114883</td><td char="." align="char">1.22271</td><td align="left">6.46E-04</td></tr><tr><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">3630</td><td char="." align="char">0.11103</td><td char="." align="char">0.938161</td><td align="left">0.986</td></tr><tr><td align="left">Diseases of the digestive system</td><td char="." align="char">1569</td><td char="." align="char">0.0479905</td><td char="." align="char">0.805347</td><td align="left">0.989</td></tr><tr><td align="left">Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism</td><td char="." align="char">1170</td><td char="." align="char">0.0357864</td><td char="." align="char">0.7873</td><td align="left">0.981</td></tr><tr><td align="left">Diseases of the circulatory system</td><td char="." align="char">921</td><td char="." align="char">0.0281703</td><td char="." align="char">0.434352</td><td align="left">0.988</td></tr><tr><td align="left">Congenital malformations, deformations and chromosomal abnormalities</td><td char="." align="char">879</td><td char="." align="char">0.0268857</td><td char="." align="char">0.194007</td><td align="left">0.985</td></tr><tr><td align="left">Diseases of the musculoskeletal system and connective tissue</td><td char="." align="char">671</td><td char="." align="char">0.0205236</td><td char="." align="char">0.540506</td><td align="left">0.981</td></tr><tr><td align="left">Diseases of the respiratory system</td><td char="." align="char">652</td><td char="." align="char">0.0199425</td><td char="." align="char">0.62028</td><td align="left">0.986</td></tr><tr><td align="left">Diseases of the genitourinary system</td><td char="." align="char">565</td><td char="." align="char">0.0172815</td><td char="." align="char">0.35427</td><td align="left">0.979</td></tr><tr><td align="left">Diseases of the skin and subcutaneous tissue</td><td char="." align="char">417</td><td char="." align="char">0.0127546</td><td char="." align="char">0.451164</td><td align="left">0.984</td></tr><tr><td align="left">Mental and behavioral disorders</td><td char="." align="char">183</td><td char="." align="char">0.00559736</td><td char="." align="char">0.166903</td><td align="left">0.976</td></tr><tr><td align="left">Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified</td><td char="." align="char">175</td><td char="." align="char">0.00535266</td><td char="." align="char">0.772496</td><td align="left">0.959</td></tr><tr><td align="left">Diseases of the ear and mastoid process</td><td char="." align="char">128</td><td char="." align="char">0.00391509</td><td char="." align="char">0.0789142</td><td align="left">0.981</td></tr><tr><td align="left">Pregnancy, childbirth and the puerperium</td><td char="." align="char">121</td><td char="." align="char">0.00370098</td><td char="." align="char">0.667658</td><td align="left">0.984</td></tr><tr><td align="left">Factors influencing health status and contact with health services</td><td char="." align="char">91</td><td char="." align="char">0.00278339</td><td char="." align="char">0.91295</td><td align="left">0.868</td></tr><tr><td align="left">Certain conditions originating in the perinatal period</td><td char="." align="char">82</td><td char="." align="char">0.00250811</td><td char="." align="char">0.25855</td><td align="left">0.977</td></tr><tr><td align="left">Injury, poisoning and certain other consequences of external causes</td><td char="." align="char">62</td><td char="." align="char">0.00189637</td><td char="." align="char">0.570176</td><td align="left">0.941</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>See text for definition.</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Comorbidities of 20 ICD-10 main classifications for bacteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ICD-10_main_classification</th><th align="left">Number of comorbidities</th><th align="left">Fraction of comorbidities</th><th align="left">Relative risk<sup>a</sup></th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Certain infectious and parasitic diseases</td><td char="." align="char">1849</td><td char="." align="char">0.276011</td><td char="." align="char">2.93761</td><td align="left">1.41E-113</td></tr><tr><td align="left">Neoplasms</td><td char="." align="char">1344</td><td char="." align="char">0.200627</td><td char="." align="char">1.24589</td><td align="left">1.10E-06</td></tr><tr><td align="left">Diseases of the eye and adnexa</td><td char="." align="char">1075</td><td char="." align="char">0.160472</td><td char="." align="char">1.06041</td><td align="left">0.332</td></tr><tr><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">558</td><td char="." align="char">0.083296</td><td char="." align="char">0.703822</td><td align="left">0.976</td></tr><tr><td align="left">Diseases of the digestive system</td><td char="." align="char">293</td><td char="." align="char">0.0437379</td><td char="." align="char">0.733983</td><td align="left">0.963</td></tr><tr><td align="left">Diseases of the genitourinary system</td><td char="." align="char">213</td><td char="." align="char">0.0317958</td><td char="." align="char">0.651814</td><td align="left">0.969</td></tr><tr><td align="left">Diseases of the circulatory system</td><td char="." align="char">198</td><td char="." align="char">0.0295567</td><td char="." align="char">0.455728</td><td align="left">0.973</td></tr><tr><td align="left">Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism</td><td char="." align="char">183</td><td char="." align="char">0.0273175</td><td char="." align="char">0.600985</td><td align="left">0.964</td></tr><tr><td align="left">Congenital malformations, deformations and chromosomal abnormalities</td><td char="." align="char">171</td><td char="." align="char">0.0255262</td><td char="." align="char">0.184197</td><td align="left">0.971</td></tr><tr><td align="left">Diseases of the musculoskeletal system and connective tissue</td><td char="." align="char">170</td><td char="." align="char">0.0253769</td><td char="." align="char">0.668321</td><td align="left">0.968</td></tr><tr><td align="left">Diseases of the nervous system</td><td char="." align="char">160</td><td char="." align="char">0.0238842</td><td char="." align="char">0.191073</td><td align="left">0.973</td></tr><tr><td align="left">Diseases of the skin and subcutaneous tissue</td><td char="." align="char">139</td><td char="." align="char">0.0207494</td><td char="." align="char">0.733958</td><td align="left">0.972</td></tr><tr><td align="left">Diseases of the respiratory system</td><td char="." align="char">131</td><td char="." align="char">0.0195552</td><td char="." align="char">0.608233</td><td align="left">0.975</td></tr><tr><td align="left">Mental and behavioural disorders</td><td char="." align="char">71</td><td char="." align="char">0.0105986</td><td char="." align="char">0.316031</td><td align="left">0.972</td></tr><tr><td align="left">Pregnancy, childbirth and the puerperium</td><td char="." align="char">46</td><td char="." align="char">0.0068667</td><td char="." align="char">1.23875</td><td align="left">0.72</td></tr><tr><td align="left">Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified</td><td char="." align="char">33</td><td char="." align="char">0.00492611</td><td char="." align="char">0.710936</td><td align="left">0.913</td></tr><tr><td align="left">Factors influencing health status and contact with health services</td><td char="." align="char">23</td><td char="." align="char">0.00343335</td><td char="." align="char">1.12614</td><td align="left">0.98</td></tr><tr><td align="left">Diseases of the ear and mastoid process</td><td char="." align="char">22</td><td char="." align="char">0.00328407</td><td char="." align="char">0.0661952</td><td align="left">0.988</td></tr><tr><td align="left">Certain conditions originating in the perinatal period</td><td char="." align="char">15</td><td char="." align="char">0.00223914</td><td char="." align="char">0.230823</td><td align="left">0.969</td></tr><tr><td align="left">Injury, poisoning and certain other consequences of external causes</td><td char="." align="char">5</td><td char="." align="char">0.00074638</td><td char="." align="char">0.224412</td><td align="left">0.885</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>See text for definition.</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec6">
      <title>Common complex diseases and pathogens</title>
      <p id="Par9">Common complex diseases are diseases that are penetrant in the population and typically follow non-Mendelian patterns. They typically arise from a series of genetic and environmental factors that perhaps include infectious diseases. Four common complex diseases, Type 2 diabetes (T2D), Atherosclerosis, Inflammatory bowel disease (IBD) and Alzheimer’s diseases and their associations to infectious diseases were assessed. Table <xref rid="Tab3" ref-type="table">3</xref> demonstrates the top 10 pathogens for each disease. The complete lists including the MOA human proteins of all pathogens for these four diseases can be found in Supplementary Materials, Table <xref rid="MOESM2" ref-type="media">S1.1</xref>–<xref rid="MOESM2" ref-type="media">S1.4</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Top 10 pathogens associated with 4 common complex diseases: Type 2 diabetes, Atherosclerosis, Inflammatory bowel disease, and Alzheimer’s disease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Taxid</th><th align="left">Pathogen name</th><th align="left">Pathogen type</th><th align="left">J-score</th><th align="left"><italic>p</italic> value</th><th align="left">q-value</th></tr></thead><tbody><tr><td align="left" colspan="6"><bold>Type 2 diabetes</bold></td></tr><tr><td align="left">11678</td><td align="left">Human immunodeficiency virus type 1 group M subtype B (isolate BH10)</td><td align="left">Infections caused by ssRNA-RT viruses</td><td char="." align="char">0.0226</td><td align="left">8.11E-06</td><td char="." align="char">0.00292</td></tr><tr><td align="left">10360</td><td align="left">Human cytomegalovirus (strain AD169)</td><td align="left">Infections caused by dsDNA viruses</td><td char="." align="char">0.0169</td><td align="left">0.000625</td><td char="." align="char">0.01437</td></tr><tr><td align="left">11108</td><td align="left">Hepatitis C virus genotype 1a (isolate H)</td><td align="left">Infections caused by + ssRNA viruses</td><td char="." align="char">0.0166</td><td align="left">0.000925</td><td char="." align="char">0.00867</td></tr><tr><td align="left">333761</td><td align="left">Human papillomavirus type 18</td><td align="left">Infections caused by dsDNA viruses</td><td char="." align="char">0.0148</td><td align="left">0.000578</td><td char="." align="char">0.0264</td></tr><tr><td align="left">10600</td><td align="left">Human papillomavirus type 6b</td><td align="left">Infections caused by dsDNA viruses</td><td char="." align="char">0.0136</td><td align="left">0.00495</td><td char="." align="char">0.0242</td></tr><tr><td align="left">82830</td><td align="left">Epstein-Barr virus (strain AG876)</td><td align="left">Infections caused by dsDNA viruses</td><td char="." align="char">0.0134</td><td align="left">0.00105</td><td char="." align="char">0.0145</td></tr><tr><td align="left" colspan="6"><bold>Atherosclerosis</bold></td></tr><tr><td align="left">333284</td><td align="left">Hepatitis C virus genotype 1b (isolate Con1)</td><td align="left">Infections caused by + ssRNA viruses</td><td char="." align="char">0.0179</td><td align="left">0.00031</td><td char="." align="char">0.0445</td></tr><tr><td align="left">10600</td><td align="left">Human papillomavirus type 6b</td><td align="left">Infections caused by dsDNA viruses</td><td char="." align="char">0.0174</td><td align="left">0.00060</td><td char="." align="char">0.0183</td></tr><tr><td align="left">41856</td><td align="left">Hepatitis C virus genotype 1</td><td align="left">Infections caused by + ssRNA viruses</td><td char="." align="char">0.0164</td><td align="left">0.00144</td><td char="." align="char">0.0357</td></tr><tr><td align="left">11103</td><td align="left">Hepacivirus C</td><td align="left">Infections caused by + ssRNA viruses</td><td char="." align="char">0.0145</td><td align="left">1.17E-05</td><td char="." align="char">0.0004</td></tr><tr><td align="left">85962</td><td align="left">Helicobacter pylori (strain ATCC 700392/26695)</td><td align="left">Infections caused by epsilon proteobacteria</td><td char="." align="char">0.0112</td><td align="left">4.17E-05</td><td char="." align="char">0.0002</td></tr><tr><td align="left">10280</td><td align="left">Molluscum contagiosum virus subtype 1</td><td align="left">Infections caused by dsDNA viruses</td><td char="." align="char">0.0070</td><td align="left">0.0188</td><td char="." align="char">0.0492</td></tr><tr><td align="left" colspan="6"><bold>Inflammatory bowel disease</bold></td></tr><tr><td align="left">11706</td><td align="left">Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)</td><td align="left">Infections caused by ssRNA-RT viruses</td><td char="." align="char">0.0274</td><td align="left">4.94E-06</td><td char="." align="char">2.33E-05</td></tr><tr><td align="left">211044</td><td align="left">Influenza A virus (strain A/Puerto Rico/8/1934 H1N1)</td><td align="left">Infections caused by -ssRNA viruses</td><td char="." align="char">0.0255</td><td align="left">8.93E-05</td><td char="." align="char">0.0005</td></tr><tr><td align="left">11044</td><td align="left">Rubella virus (strain RA27/3 vaccine)</td><td align="left">Infections caused by + ssRNA viruses</td><td char="." align="char">0.0255</td><td align="left">9.06E-05</td><td char="." align="char">0.0005</td></tr><tr><td align="left">632</td><td align="left">Yersinia pestis</td><td align="left">Infections caused by enterobacteria</td><td char="." align="char">0.0248</td><td align="left">0.00015</td><td char="." align="char">0.0017</td></tr><tr><td align="left">158611</td><td align="left">Influenza A virus (A/Paris/908/97(H3N2))</td><td align="left">Infections caused by -ssRNA viruses</td><td char="." align="char">0.0169</td><td align="left">0.00327</td><td char="." align="char">0.0239</td></tr><tr><td align="left">10280</td><td align="left">Molluscum contagiosum virus subtype 1</td><td align="left">Infections caused by dsDNA viruses</td><td char="." align="char">0.0157</td><td align="left">2.43E-10</td><td char="." align="char">9.00E-10</td></tr><tr><td align="left">382835</td><td align="left">Influenza A virus (A/WSN/1933(H1N1))</td><td align="left">Infections caused by -ssRNA viruses</td><td char="." align="char">0.0151</td><td align="left">6.67E-05</td><td char="." align="char">0.0020</td></tr><tr><td align="left">928302</td><td align="left">Hepatitis B virus genotype C subtype ayr (isolate Human/Japan/Okamoto/-)</td><td align="left">Infections caused by dsDNA-RT viruses</td><td char="." align="char">0.0131</td><td align="left">0.00125</td><td char="." align="char">0.0107</td></tr><tr><td align="left">11103</td><td align="left">Hepacivirus C</td><td align="left">Infections caused by + ssRNA viruses</td><td char="." align="char">0.0070</td><td align="left">0.00022</td><td char="." align="char">0.0045</td></tr><tr><td align="left">290579</td><td align="left">Human immunodeficiency virus type 1 group M subtype B (isolate Lai)</td><td align="left">Infections caused by ssRNA-RT viruses</td><td char="." align="char">0.0070</td><td align="left">0.00036</td><td char="." align="char">0.0052</td></tr><tr><td align="left" colspan="6"><bold>Alzheimer’s disease</bold></td></tr><tr><td align="left">1891767</td><td align="left">Simian virus 40</td><td align="left">Infections caused by ssRNA-RT viruses</td><td char="." align="char">0.0185</td><td align="left">0.00066</td><td char="." align="char">0.0053</td></tr><tr><td align="left">211044</td><td align="left">Influenza A virus (strain A/Puerto Rico/8/1934 H1N1)</td><td align="left">Infections caused by -ssRNA viruses</td><td char="." align="char">0.0157</td><td align="left">0.0044</td><td char="." align="char">0.0149</td></tr><tr><td align="left">11044</td><td align="left">Rubella virus (strain RA27/3 vaccine)</td><td align="left">Infections caused by + ssRNA viruses</td><td char="." align="char">0.0157</td><td align="left">0.0045</td><td char="." align="char">0.0151</td></tr><tr><td align="left">381518</td><td align="left">Influenza A virus (strain A/Wilson-Smith/1933 H1N1)</td><td align="left">Infections caused by -ssRNA viruses</td><td char="." align="char">0.0156</td><td align="left">0.0021</td><td char="." align="char">0.0074</td></tr><tr><td align="left">796210</td><td align="left">Bunyavirus La Crosse (isolate Human/United States/L78/1978)</td><td align="left">Infections caused by -ssRNA viruses</td><td char="." align="char">0.0135</td><td align="left">0.0032</td><td char="." align="char">0.0329</td></tr><tr><td align="left">69156</td><td align="left">Murid herpesvirus 1 (strain K181)</td><td align="left">Infections caused by dsDNA viruses</td><td char="." align="char">0.0109</td><td align="left">0.0018</td><td char="." align="char">0.0253</td></tr><tr><td align="left">10915</td><td align="left">Rotavirus A (strain RVA/Pig/United States/OSU/1977/G5P9[7])</td><td align="left">Infections caused by dsRNA viruses</td><td char="." align="char">0.0091</td><td align="left">7.81E-05</td><td char="." align="char">0.0013</td></tr><tr><td align="left">31684</td><td align="left">Simian immunodeficiency virus agm.grivet (isolate AGM gr-1)</td><td align="left">Infections caused by ssRNA-RT viruses</td><td char="." align="char">0.0086</td><td align="left">0.0028</td><td char="." align="char">0.0242</td></tr><tr><td align="left">73475</td><td align="left">Chicken anemia virus (isolate Germany Cuxhaven-1)</td><td align="left">Infections caused by ssDNA viruses</td><td char="." align="char">0.0061</td><td align="left">0.0019</td><td char="." align="char">0.0205</td></tr><tr><td align="left">11707</td><td align="left">Human immunodeficiency virus type 1 group M subtype B (isolate HXB3)</td><td align="left">Infections caused by ssRNA-RT viruses</td><td char="." align="char">0.0060</td><td align="left">0.0026</td><td char="." align="char">0.0153</td></tr></tbody></table></table-wrap></p>
      <p id="Par10">Insulin resistance, a major characteristic of Type 2 diabetes, may be the consequence of frequent bouts of pathogen exposure and mild inflammatory response<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. 6 significant viruses were predicted to be associated with Type 2 diabetes (q-value &lt; 0.05) (see Table <xref rid="MOESM2" ref-type="media">S1.1</xref>). Human immunodeficiency virus type 1 (HIV) is predicted to be the most significant virus associated with T2D. HIV-infected adults have a 3.8% higher incidence of diabetes mellitus than the general adult population<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Of the viruses associated with Type 2 diabetes, Epstein-Barr virus (strain AG876) (EBV) is prominent. The literature supports a link between Type 1 diabetes and EBV<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. To identify the possible MOA proteins of EBV’s association with Type 2 diabetes, we examine the shared proteins of the EBV interactome with the MOA proteins of Type 2 diabetes predicted by MEDICASCY<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. A total of 11 proteins are shared between them. MGST1 is associated with tissue damage that are part of diabetes<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. All 6 viruses interact with CTSB. CTSB was found to contribute to Autophagy-related 7 (Atg7)-induced inflammatory response resulting in aggravation of lipotoxicity<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and increased T2D risk<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>.</p>
      <p id="Par11">Atherosclerosis is characterized by the formation of cholesterol plaque(s) in the walls of the arteries. 5 significant viruses and 1 significant bacteria are predicted to be associated with Atherosclerosis (see Table <xref rid="MOESM2" ref-type="media">S1.2</xref>). The most significant is <italic>helicobacter pylori</italic>. Interestingly, it is significantly associated with subclinical coronary atherosclerosis in healthy subjects<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Human papillomavirus (HPV) is associated with increased prevalence of cardiovascular disease post-infection. This may be due to HPV increasing pro-inflammatory activity and altered lipid metabolism<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Three hepatitis C virus (HCV) strains were predicted to be associated with Atherosclerosis; HCV infection is known to be a risk factor for Atherosclerosis<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. 4 of the 6 pathogens interact with human protein ITGB1. A bioinformatics study suggests that ITGB1 is a key gene associated with carotid atherosclerosis<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>.</p>
      <p id="Par12">Inflammatory Bowel Disease is an umbrella condition represented by Crohn’s disease and ulcerative colitis primarily characterized by intestinal inflammation. There are 10 significant viruses and 3 significant bacteria predicted to be associated with IBD (see Table <xref rid="MOESM2" ref-type="media">S1.3</xref>). Literature suggests that dysregulation of intestinal mucosa may contribute to the pathogenesis of IBD<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Furthermore, gut microbiota play a major role in the pathogenesis of IBD as it may promote inflammation<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Some infectious diseases can alter the homeostasis of the gut microbiota, thus, contributing to the intestinal inflammation<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Influenza A virus (H1N1) is predicted to be significantly associated with IBD, a prediction supported by literature evidence<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Additionally, HIV is predicted to be significantly associated with IBD; indeed, HIV infection causes onset of Crohn’s disease<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Among the 90 unique MOA proteins of pathogens’ association with IBD (see Table <xref rid="MOESM2" ref-type="media">S1.3</xref>, union of all MOA proteins), ITGB1 and GSN have the largest numbers (6 and 5 of 13) of interacting pathogens. ITGB1 plays an important role in the pathogenesis of IBD<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>; GSN is a potential biomarker for ulcerative colitis<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>.</p>
      <p id="Par13">Alzheimer’s disease (AD), a neurodegenerative disease characterized by memory loss and cognitive impairment, may result from the amyloid cascade or the tau hyperphosphorylation<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. There is a theory that infections can seed some cases of AD<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Indeed, there are 10 significant viruses predicted to be associated with Alzheimer’s disease (see Table <xref rid="MOESM2" ref-type="media">S1.4</xref>). Two strains of H1N1 are predicted to be significantly associated with AD. It has been shown by three studies that at least one flu vaccination is associated with a 17% <italic>decrease</italic> in AD incidence<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Among the 43 proteins interacting with H1N1, PPIA plays role in tau oligomerization and amyloid processing in AD<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>; RBBP7 is a mediator against neuronal loss in AD<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Simian virus 40 is predicted to be associated to AD. One study found that its antigen expression induces AD like pathology in mice<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Simian virus interacts with FBXW11 that is found to be related to AD alleviation<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>.</p>
      <p id="Par14">It is possible that infectious diseases may encourage damaging molecular processes in the specific human body/tissue yielding key characteristics of some common complex diseases such as persistent inflammation. It may also be that individuals have to encounter a series of these pathogens before subsequently developing a common complex disease.</p>
    </sec>
    <sec id="Sec7">
      <title>Prevalent pathogens and diseases</title>
      <p id="Par15">Next, we will explore the disease comorbidities associated with the following prevalent infectious pathogens: EBV (strain B95-8) (taxid 10377), Influenza A virus (strain A/New York/1682/2009(H1N1)) (taxid 643960), <italic>Escherichia coli</italic> (taxid 562) and Salmonella typhimurium (taxid 90371). Table <xref rid="Tab4" ref-type="table">4</xref> shows the top 10 comorbidities for each pathogen. Full lists including the MOA proteins are found in Supplementary Table <xref rid="MOESM2" ref-type="media">S2.1</xref>–<xref rid="MOESM2" ref-type="media">S2.4</xref>.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Top 10 disease comorbidities associated with 4 common infectious pathogens: Epstein-Barr virus (EBV) (strain B95-8), Influenza A virus (strain A/New York/1682/2009(H1N1)), Escherichia coli (Taxid 562), and Salmonella typhimurium (Taxid 90371).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Disease</th><th align="left">ICD-10 group</th><th align="left">J-score</th><th align="left"><italic>p</italic> value</th><th align="left">q-value</th></tr></thead><tbody><tr><td align="left" colspan="5"><bold>Epstein-Barr virus (strain B95-8) (taxid:10377)</bold></td></tr><tr><td align="left">Oligospermia</td><td align="left">Diseases of the genitourinary system</td><td char="." align="char">0.060</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Carbohydrate metabolic disorder</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.056</td><td align="left">1.79E−05</td><td align="left">0.00034</td></tr><tr><td align="left">Pellagra</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.055</td><td align="left">3.82E−05</td><td align="left">0.00069</td></tr><tr><td align="left">Pyridoxine deficiency anemia</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.055</td><td align="left">0.00012</td><td align="left">0.00186</td></tr><tr><td align="left">Gestational diabetes</td><td align="left">Pregnancy, childbirth and the puerperium</td><td char="." align="char">0.055</td><td align="left">1.49E−05</td><td align="left">0.00029</td></tr><tr><td align="left">Kwashiorkor</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.054</td><td align="left">0.00025</td><td align="left">0.00363</td></tr><tr><td align="left">Lipid metabolism disorder</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.054</td><td align="left">7.34E−05</td><td align="left">0.00125</td></tr><tr><td align="left">Beriberi</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.054</td><td align="left">0.00031</td><td align="left">0.00434</td></tr><tr><td align="left">Ariboflavinosis</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.054</td><td align="left">0.00031</td><td align="left">0.00434</td></tr><tr><td align="left">Osteomalacia</td><td align="left">Diseases of the musculoskeletal system and connective tissue</td><td char="." align="char">0.054</td><td align="left">0.00034</td><td align="left">0.00476</td></tr><tr><td align="left" colspan="5"><bold>Influenza A virus (strain A/New York/1682/2009(H1N1)) (taxid:643960)</bold></td></tr><tr><td align="left">Tay-Sachs disease</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.033</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Sandhoff disease</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.033</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">GM1 gangliosidosis</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.033</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Wolman disease</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.033</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Metachromatic leukodystrophy</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.032</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Hemoglobinopathy</td><td align="left">Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism</td><td char="." align="char">0.032</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Mucopolysaccharidosis III</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.032</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Coronary stenosis</td><td align="left">Injury, poisoning and certain other consequences of external causes</td><td char="." align="char">0.032</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Lysosomal storage disease</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.031</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Krabbe disease</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.031</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left" colspan="5"><bold>Escherichia coli (taxid: 562)</bold></td></tr><tr><td align="left">Uveitis</td><td align="left">Diseases of the eye and adnexa</td><td char="." align="char">0.0077</td><td align="left">5.13E−08</td><td align="left">3.70E−05</td></tr><tr><td align="left">Pulmonary embolism</td><td align="left">Diseases of the circulatory system</td><td char="." align="char">0.0077</td><td align="left">5.63E−06</td><td align="left">0.00073</td></tr><tr><td align="left">Endocrine system disease</td><td align="left">Endocrine, nutritional and metabolic diseases</td><td char="." align="char">0.0077</td><td align="left">8.15E−09</td><td align="left">1.47E−05</td></tr><tr><td align="left">Nephrocalcinosis</td><td align="left">Diseases of the genitourinary system</td><td char="." align="char">0.0074</td><td align="left">3.76E−08</td><td align="left">3.39E−05</td></tr><tr><td align="left">Hypertension</td><td align="left">Diseases of the circulatory system</td><td char="." align="char">0.0074</td><td align="left">2.20E−09</td><td align="left">7.94E−06</td></tr><tr><td align="left">Iritis</td><td align="left">Diseases of the eye and adnexa</td><td char="." align="char">0.0071</td><td align="left">2.77E−08</td><td align="left">3.33E−05</td></tr><tr><td align="left">Gingival recession</td><td align="left">Diseases of the digestive system</td><td char="." align="char">0.0068</td><td align="left">8.31E−07</td><td align="left">0.00037</td></tr><tr><td align="left">Focal segmental glomerulosclerosis</td><td align="left">Diseases of the genitourinary system</td><td char="." align="char">0.0067</td><td align="left">4.59E−07</td><td align="left">0.00024</td></tr><tr><td align="left">Dental caries</td><td align="left">Diseases of the digestive system</td><td char="." align="char">0.0066</td><td align="left">1.18E−06</td><td align="left">0.00042</td></tr><tr><td align="left">Anovulation</td><td align="left">Diseases of the genitourinary system</td><td char="." align="char">0.0065</td><td align="left">1.54E−06</td><td align="left">0.00047</td></tr><tr><td align="left" colspan="5"><bold>Salmonella typhimurium (taxid: 90371)</bold></td></tr><tr><td align="left">Pustulosis of palm and sole</td><td align="left">Diseases of the skin and subcutaneous tissue</td><td char="." align="char">0.0039</td><td align="left">1.79E−05</td><td align="left">0.0073</td></tr><tr><td align="left">Obstructive sleep apnea</td><td align="left">Diseases of the nervous system</td><td char="." align="char">0.0038</td><td align="left">2.20E−05</td><td align="left">0.0073</td></tr><tr><td align="left">psoriasis</td><td align="left">Diseases of the skin and subcutaneous tissue</td><td char="." align="char">0.0038</td><td align="left">2.29E−05</td><td align="left">0.0073</td></tr><tr><td align="left">Hyperglycemia</td><td align="left">Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified</td><td char="." align="char">0.0033</td><td align="left">4.57E−05</td><td align="left">0.0073</td></tr><tr><td align="left">Chronic kidney disease</td><td align="left">Diseases of the genitourinary system</td><td char="." align="char">0.0030</td><td align="left">7.35E−06</td><td align="left">0.0073</td></tr><tr><td align="left">Uveitis</td><td align="left">Diseases of the eye and adnexa</td><td char="." align="char">0.0026</td><td align="left">1.77E−05</td><td align="left">0.0073</td></tr><tr><td align="left">Anterior uveitis</td><td align="left">Diseases of the eye and adnexa</td><td char="." align="char">0.0026</td><td align="left">5.43E−09</td><td align="left">1.96E−05</td></tr><tr><td align="left">Narcolepsy</td><td align="left">Diseases of the nervous system</td><td char="." align="char">0.0025</td><td align="left">2.32E−05</td><td align="left">0.0073</td></tr><tr><td align="left">Gingival recession</td><td align="left">Diseases of the digestive system</td><td char="." align="char">0.0024</td><td align="left">2.66E−05</td><td align="left">0.0073</td></tr><tr><td align="left">Dental caries</td><td align="left">Diseases of the digestive system</td><td char="." align="char">0.0024</td><td align="left">3.06E−05</td><td align="left">0.0073</td></tr></tbody></table></table-wrap></p>
      <p id="Par16">There were 408 significant comorbidities associated with EBV (strain B95-8) (see Table <xref rid="MOESM2" ref-type="media">S2.1</xref>). Of these, 167 and 130 involve Endocrine nutritional and metabolic diseases and Neoplasms, respectively. Oligospermia, characterized by a low sperm count is the top associated comorbidity with EBV. Viral infections may contribute to male infertility via initiating inflammatory reactions that yield an increase in reactive oxygen species causing testicular damage<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Lipid metabolism disorder and carbohydrate metabolic disorder were predicted to be significant diseases associated with EBV. As another example, we examined the EBV interactome proteins of association with Gestational diabetes. We found 266 proteins that interact with EBV. The top 5 proteins prioritized by LeMeDISCO are STX7, STX10, CDIPT, GLIPR2, SNRPA. STX7 is upregulated in T2D<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, and STX10 is differentially methylated in the offspring of women with maternal diabetes<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. CDIPT was hypomethylated and up-regulated in the fetus of mice with Maternal Gestational Diabetes<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. SNRPA was found to be associated with metabolic syndromes<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>.</p>
      <p id="Par17">There were 211 significant comorbidities associated with Influenza A virus (strain A/New York/1682/2009(H1N1) (see Table <xref rid="MOESM2" ref-type="media">S2.2</xref>). The top 2 groups of diseases involve 33 Endocrine, nutritional and metabolic diseases and 26 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism. The top 2 significant human comorbid diseases for Influenza A virus (flu) were Tay-Sachs disease (mutations in HEXA) and Sandhoff disease (mutations in HEXB) that are very similar rare genetic diseases. There is no direct interaction of flu with those two proteins. However, the human proteins in the flu-human interactome of HK1 protein interacts with both HEXA and HEXB<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, and they share a pathway involving carbohydrate metabolism<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Another significant comorbid disease is coronary stenosis. Studies have suggested an association between influenza and cardiovascular diseases due to the activation of inflammatory pathways<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. We shall examine this in more detail in the following “<xref rid="Sec10" ref-type="sec">Heart disease and flu</xref>” section. There were several other rare diseases predicted to be associated with Influenza A. Some involve the immune mechanism and result in a fatal outcome from contracting the flu. For example, thrombocytopenia can be induced by flu<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> and flu vaccination<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. However, we do not know which genes are responsible for thrombocytopenia. Rather, we list 66 candidate genes in Table <xref rid="MOESM2" ref-type="media">S2.2</xref> for future investigation.</p>
      <p id="Par18">There were 380 significant comorbidities associated with <italic>Escherichia coli</italic> (taxid 562) (see Table <xref rid="MOESM2" ref-type="media">S2.3</xref>). 289 involve Certain infectious and parasitic diseases. The top predicted significant comorbid disease for <italic>Escherichia coli</italic> (<italic>E. coli</italic>) was Uveitis. Amazingly, <italic>E.coli</italic> is beneficial for treating Uveitis<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. Among the 5 interactomes of <italic>E.coli</italic> for Uveitis, deficiency of the top ranked SERPINA1 is a uveitis risk factor<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Hypertension, renal tubular acidosis and cardiovascular syphilis were predicted to be other significant comorbidities to <italic>E. coli.</italic> In fact, <italic>E. coli</italic> contamination in drinking water increases the risk of hypertension, renal impairment and cardiovascular disease<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>.</p>
      <p id="Par19">There were 50 significant comorbidities associated with <italic>Salmonella typhimurium</italic> (see Table <xref rid="MOESM2" ref-type="media">S2.4</xref>). 14 and 10 of them, respectively, are Endocrine, nutritional and metabolic diseases &amp; Diseases of the genitourinary system. The third most significant comorbid disease is psoriasis and Salmonella typhimurium is proposed as photochemotherapy agent for psoriasis<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. Another example of significant comorbidity is hyperglycemia, which is characterized by high blood sugar. Salmonella infection causes hyperglycemia in pigs<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>.</p>
    </sec>
    <sec id="Sec8">
      <title>On the oncogenic/oncolytic potential of pathogens</title>
      <p id="Par20">The above results (see Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>) show that Neoplasms have the largest relative risk as being caused by viruses and the second largest relative risk as being caused by bacterial infection compared to general causes. Thus, it is worthwhile to examine the oncogenic/oncolytic potential of pathogens in detail.</p>
      <p id="Par21">We define an onco_index, a <italic>p</italic> value characterizing the overlap of pathogen’s interactome with the 723 cancer drivers given in the COSMIC database<sup><xref ref-type="bibr" rid="CR67">67</xref></sup> to detect pathogens associated with cancers (either oncogenic or oncolytic) from others. An onco_index &lt; 0.05 is considered to have oncogenic/oncolytic potential. Table <xref rid="Tab5" ref-type="table">5</xref> shows the top 10 cancer associated viruses and bacteria. A complete list of predicted oncogenic/oncolytic pathogens (109 viruses and 15 bacteria) whose onco-index <italic>p</italic> value &lt; 0.05 is given in Supplementary Tables <xref rid="MOESM2" ref-type="media">S3</xref> and <xref rid="MOESM2" ref-type="media">S4</xref> along with possible MOA proteins, denoted as onco_MOA protein. These are defined as those pathogen proteins that interact with the 723 cancer drivers that have documented literature evidence of oncogenic/oncolytic potential. Of the 124 pathogens 93(75%) have literature evidence, 55(38%) of having oncogenic(oncolytic) potential.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Top 10 most oncogenic/oncolytic viruses and bacteria ranked by their index.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">TaxID</th><th align="left">Pathogen name</th><th align="left">Onco_index</th></tr></thead><tbody><tr><td align="left" colspan="3"><bold>Viruses</bold></td></tr><tr><td align="left">41856</td><td align="left">Hepatitis C virus genotype 1</td><td align="left">7.53E−10</td></tr><tr><td align="left">11706</td><td align="left">Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)</td><td align="left">1.64E−09</td></tr><tr><td align="left">28282</td><td align="left">Human adenovirus A serotype 12</td><td align="left">3.43E−09</td></tr><tr><td align="left">333760</td><td align="left">Human papillomavirus type 16</td><td align="left">4.64E−09</td></tr><tr><td align="left">33708</td><td align="left">Murid herpesvirus 4</td><td align="left">2.59E−08</td></tr><tr><td align="left">28285</td><td align="left">Human adenovirus C serotype 5</td><td align="left">4.28E−08</td></tr><tr><td align="left">11927</td><td align="left">Human T-cell leukemia virus 1 (isolate Caribbea HS-35 subtype A)</td><td align="left">1.67E−07</td></tr><tr><td align="left">11926</td><td align="left">Human T-cell leukemia virus 1 (strain Japan ATK-1 subtype A)</td><td align="left">4.39E−07</td></tr><tr><td align="left">868565</td><td align="left">Human herpesvirus 8 type P (isolate GK18)</td><td align="left">8.46E−07</td></tr><tr><td align="left">10583</td><td align="left">Human papillomavirus type 1</td><td align="left">2.83E−06</td></tr><tr><td align="left" colspan="3"><bold>Bacteria</bold></td></tr><tr><td align="left">632</td><td align="left">Yersinia pestis</td><td align="left">4.95E−20</td></tr><tr><td align="left">1392</td><td align="left">Bacillus anthracis</td><td align="left">2.86E−16</td></tr><tr><td align="left">177416</td><td align="left">Francisella tularensis subsp. tularensis (strain SCHU S4/Schu 4)</td><td align="left">1.45E−10</td></tr><tr><td align="left">562</td><td align="left">Escherichia coli</td><td align="left">8.17E−06</td></tr><tr><td align="left">623</td><td align="left">Shigella flexneri</td><td align="left">6.02E−05</td></tr><tr><td align="left">1505</td><td align="left">Paeniclostridium sordellii</td><td align="left">0.000245613</td></tr><tr><td align="left">1639</td><td align="left">Listeria monocytogenes</td><td align="left">0.000552402</td></tr><tr><td align="left">272635</td><td align="left">Mycoplasma pulmonis (strain UAB CTIP)</td><td align="left">0.00150676</td></tr><tr><td align="left">622</td><td align="left">Shigella dysenteriae</td><td align="left">0.002832269</td></tr><tr><td align="left">287</td><td align="left">Pseudomonas aeruginosa</td><td align="left">0.003743935</td></tr></tbody></table></table-wrap></p>
      <p id="Par22">For those predictions with literature evidence, we have the putative molecular basis of associations that can be validated by experimentalists. About ~ 1/4 of the predictions are novel and worthy of further investigation. To demonstrate how the MOA proteins explain the cancers a given pathogen is associated with, we present the example of the first discovered human tumor virus associated with Epstein-Barr virus<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. There are 885 interactome proteins for EBV(strain AG876), 64 proteins are cancer drivers according to COSMIC<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. Among these are EGFR and ERBB2, which are well-known tumor drivers<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>.</p>
    </sec>
    <sec id="Sec9">
      <title>Distinguishing oncolytic from oncogenic pathogens</title>
      <p id="Par23">While the above onco_index distinguishes pathogens associated with cancers from others, some of the cancer associated pathogens can be oncolytic. To distinguish oncolytic from oncogenic potential of pathogens, we examined the interactomes of the 93 pathogens having literature evidence of being oncogenic (total 55) or oncolytic (total 38) and derived oncolytic and oncogenic propensities for each pathogen. First, the oncolytic/oncogenic propensity of an interactome protein of pathogen is derived by calculating a <italic>p</italic> value of its association with oncolytic/oncogenic pathogens. Then the oncolytic/oncogenic propensity of pathogen is calculated as the sum of its interactomes’ propensity (see “<xref rid="Sec13" ref-type="sec">Methods</xref>” for addition details). A jackknife test was performed on these 93 pathogens by excluding self in deriving oncolytic and oncogenic propensity. We classify a pathogen as being oncolytic if its oncolytic propensity is greater than its oncogenic propensity. The resulting Matthews correlation coefficient (MCC) of this analysis on the 93 pathogens is 0.77, the recall rate (sensitivity) is 94.7%, accuracy 88.2%, and precision is 80.0%. The oncolytic/oncogenic propensity of possible cancer associated pathogens is found in Tables <xref rid="MOESM2" ref-type="media">S3</xref> and <xref rid="MOESM2" ref-type="media">S4</xref>. We then apply the oncolytic/oncogenic propensity to all the pathogens (not limited to those that are predicted cancer associated) to discover possible pathogens that might be used for cancer treatment. The oncolytic_MOA proteins are those human proteins in the given pathogen-human interactome ranked by their oncolytic propensities (see Eq. <xref rid="Equ3" ref-type="">3</xref>a). 136 pathogens with oncolytic &gt; oncogenic propensity not included in Tables <xref rid="MOESM2" ref-type="media">S3</xref> and <xref rid="MOESM2" ref-type="media">S4</xref> are listed in Table <xref rid="MOESM2" ref-type="media">S5.1</xref> ranked by oncolytic minus oncogenic propensity. Among the top, many are various strains of flu; we note that subtype H5N1 has already shown to have a curative effect on cancer<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.</p>
      <p id="Par24">In a recent work<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> we predicted that SARS-CoV-2 is likely associated with cancers by applying the 332 interactomes from ref<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. Using the same interactomes and the above method, we now additionally predict that SARS-CoV-2 is likely to be oncolytic with a propensity score of 0.017 that will rank 13th in Table <xref rid="MOESM2" ref-type="media">S5.1</xref>’s 136 predictions. Its significant oncolytic MOA proteins (propensity <italic>p</italic> value &lt; 0.05, see Eq. <xref rid="Equ3" ref-type="">3</xref>a) along with literature supports are given in Table <xref rid="MOESM2" ref-type="media">S5.2</xref>. For 10 of the 12 proteins, we have literature evidence of their associations with cancers. For example, MIN, NUP214, PABPC1, LARP4B &amp; DDX10 are established cancer drivers in the COSMIC database<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. The top protein, MIN, is associated with the risk of colorectal cancer<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. Knockdown of the second protein MOV10 leads to upregulation of INK4, a tumor suppressor<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Inhibition of the third protein NUP214 leads to cell death<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. PABPC4 plays role in the pathogenesis of colorectal cancer<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>.</p>
      <p id="Par25">While the oncolytic effect might be due to collective effect of the oncolytic proteins, many (48/147) of the top unique pathways (different from those of the oncogenic significant proteins with <italic>p</italic> value &lt; 0.05) of the significant proteins involve PIK3R1 (see Table <xref rid="MOESM2" ref-type="media">S6</xref> for unique pathways and proteins involved): e.g., CD28 dependent PI3K/Akt signaling, Signaling by cytosolic FGFR1 fusion mutants, Signaling by PDGFR in disease, etc. PIK3R1 is a known tumor suppressor<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. Another frequent protein in unique pathways is PIK3CA and its mutations cause a variety of common human tumor types<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. The above SARS-CoV-2 interactome MOV10 is involved in 12 pathways. Although it does not directly involve apoptotic pathways, its interacting partners ACIN1 and SLC25A5<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> involve Apoptosis<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. The colorectal cancer related protein PABPC4 of the SARS-CoV-2 interactome interacts with YWHAQ, YWHAZ &amp; TNFRSF10D that all involve Apoptosis<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>.</p>
    </sec>
    <sec id="Sec10">
      <title>Heart disease and flu</title>
      <p id="Par26">Studies show that heart disease is one of the most common chronic conditions of adults hospitalized with flu<sup><xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR78">78</xref></sup>; it also increases the incidence of strokes. To understand the molecular bases of this observation, we examined the significant comorbidities (q-value &lt; 0.05) belonging to the class “Diseases of the circulatory system” associated with various strains of flu. In total, we predicted 79 pairs of flu virus—Diseases of the circulatory system involving 20 strains of flu and 25 cardiovascular diseases. The 79 pairs and related putative MOA proteins are listed in Table <xref rid="MOESM2" ref-type="media">S7</xref>.</p>
      <p id="Par27">The 25 comorbid diseases ranked by the number of associated flu strains along with literature evidence are given in Table <xref rid="MOESM2" ref-type="media">S8</xref>. The top 5 diseases are: <italic>intracranial vasospasm, Dressler's syndrome, brain stem infarction, brain ischemia</italic><sup><xref ref-type="bibr" rid="CR79">79</xref></sup><italic>, lymphatic system disease</italic>. We found 12 of the diseases have supporting literature evidence for their associations with flu. The novel predictions of disease associations are useful in guiding clinicians for disease diagnosis.</p>
      <p id="Par28">Next, we analyze the most frequent MOA proteins and their pathways<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. For each human protein that interacts with flu, we count its frequency as a MOA protein in the 79 flu-heart disease pairs, each of which may contain multiple human proteins that interact with the given strain of flu. The top 100 ranked most frequent proteins are listed in Table <xref rid="MOESM2" ref-type="media">S9</xref> along with literature evidence of their association with heart disease. For the top 20 proteins, we find evidence for 9 proteins. For example, the top 1st protein, PIK3R1, is a cardiac regulator<sup><xref ref-type="bibr" rid="CR80">80</xref></sup>. The 2nd protein, GSN, is critical for heart disease<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>.</p>
      <p id="Par29">The 39 significant pathways (q-value &lt; 0.05) involving the above top 100 proteins are given in Table <xref rid="MOESM2" ref-type="media">S10</xref>. For 22 we found literature evidence of their associations with heart disease. Many of them involve protein synthesis. The top 5 pathways are <italic>Translation</italic><sup><xref ref-type="bibr" rid="CR82">82</xref></sup><italic>, Mitochondrial translation initiation</italic><sup><xref ref-type="bibr" rid="CR83">83</xref></sup><italic>, Mitochondrial translation elongation</italic><sup><xref ref-type="bibr" rid="CR83">83</xref></sup><italic>, Mitochondrial translation termination</italic><sup><xref ref-type="bibr" rid="CR83">83</xref></sup><italic>, Mitochondrial translation</italic><sup><xref ref-type="bibr" rid="CR83">83</xref></sup>. There are number of ribosomal proteins (RPS19/RPL8/RPL30A/RPL3/RPL23/RPL19/RPL15/RPL11) in these pathways that the flu viruses interact with. Studies have shown that mutations in many ribosomal proteins result in a Minute phenotype in <italic>Drosophila</italic> and Cardiomyopathy is correlated with the Minute phenotype<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>. With all the literature evidence, our novel predictions of MOA proteins and pathways are useful in guiding experimentalists for further investigations.</p>
    </sec>
    <sec id="Sec11">
      <title>PHEVIRdb web application</title>
      <p id="Par30">The PHEVIRdb web application allows researchers to access disease comorbidities and the corresponding MOA proteins associated with interactions with the respective pathogen. With multiple input options (keyword and exact search), one can input a keyword for a pathogen name or disease name or select a pathogen name and disease name from the pull down menu. The web service is freely available for academic users at <ext-link ext-link-type="uri" xlink:href="https://sites.gatech.edu/cssb/phevir/">https://sites.gatech.edu/cssb/phevir/</ext-link>. Figure <xref rid="Fig1" ref-type="fig">1</xref> shows screenshots of the web interface and an output example. The keyword search provides a fuzzy search that matches pathogen name or disease name containing the keyword. From the pull down menu, the user can select the pathogen name and disease name for an exact match search. The output can be saved and is searchable by keywords in the search box.<fig id="Fig1"><label>Figure 1</label><caption><p>Screenshots of PHEVIR webserver. (<bold>A</bold>) Web interface of PHEVIR. (<bold>B</bold>) Sample output of PHEVIR.</p></caption><graphic xlink:href="41598_2022_25412_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
  </sec>
  <sec id="Sec12">
    <title>Discussion</title>
    <p id="Par31">PHEVIR, with 77.2% recall and 37.1% precision based on large scale benchmarking, has predicted post-infection complications of 369 pathogens. Consistent with its quite general definition, our prediction that <italic>Certain infectious and parasitic diseases</italic> have the largest overall relative risk for pathogens. We also predict that <italic>Neoplasms</italic> are the only other group of diseases, on average, having a significant relative risk compared to general causes. By examining some common complex diseases associated with pathogens, oncogenic/oncolytic pathogens and heart disease association with flu, we found that many of PHEVIR’s predictions have literature evidence (which is unknown to the algorithm which views these as <italic>bona fide</italic> predictions). For all predictions, PHEVIR provides the molecular basis of each human disease-pathogen association. In addition, the onco_index and oncolytic propensity can tell whether a pathogen is potentially oncogenic or oncolytic. Importantly, the oncolytic/oncogenic propensity can distinguish oncolytic from oncogenic viruses at 88.2% accuracy and 80.0% precision. Oncolytic pathogens are a useful means of treating cancers and their MOA proteins could be targeted by small molecules or antibodies. Furthermore, PHEVIR predicted 25 heart diseases (Disease of circulatory system) associated with flu for which ~ 50% have literature evidence. These predictions as well as their corresponding MOA proteins are useful for guiding further experimental investigations on disease etiology and for clinic diagnosis. The goal is to eventually find better prevention and treatments of these diseases.</p>
    <p id="Par32">On another note, PHEVIR strongly suggests that many non-Mendelian diseases have a viral component. Indeed, 91% (3285) of the 3608 diseases we consider which cover almost all disease types have a least one viral pathogen associated with it. For the 57 bacteria, 66.7% (2405) of diseases have bacterial associated human disease comorbidities. What is important to realize is that we merely considered 312 strains of viruses and 57 different bacteria. This is clearly a tiny minority of bacterial and viral pathogens. At present, we cannot definitively differentiate whether the pathogen’s infection induces the onset of the complex disease or merely exacerbates its progression. But what this study strongly suggests is that infectious diseases and complex noninfectious diseases are not disjoint and non-interacting. Rather, their interaction is likely to be the rule rather than the exception. Some infections such as an oncolytic virus might be antagonists to the given disease while others, (e.g. oncogenic viruses) might be agonists. This does suggest that one possible means of eliminating/preventing severe diseases such as IBD, AD, and some cancers might be by eliminating the infectious diseases that might be a major contributory factor. In the case of viruses, this suggests that the broader development of antiviral vaccines or antiviral drugs is clearly needed.</p>
  </sec>
  <sec id="Sec13">
    <title>Materials and methods</title>
    <p id="Par33">A flowchart of PHEVIR method is given in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. We detail each of the steps below.<fig id="Fig2"><label>Figure 2</label><caption><p>General PHEVIR methodology. (<bold>A</bold>) Comorbidity pipeline; (<bold>B</bold>) Onco-index calculation and oncogenic/oncolytic prediction pipeline.</p></caption><graphic xlink:href="41598_2022_25412_Fig2_HTML" id="MO2"/></fig></p>
    <sec id="Sec14">
      <title>Curating human–pathogen interactomes</title>
      <p id="Par34">Host–pathogen interactome data were extracted from the HPIDB 3.0 database (<ext-link ext-link-type="uri" xlink:href="https://hpidb.igbb.msstate.edu">https://hpidb.igbb.msstate.edu</ext-link>)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Interactions with <italic>homo sapiens</italic> (taxid: 9606) and <italic>homo sapiens</italic> proteins with known UniProtKB IDs were obtained. Next, the pathogens were mapped to their corresponding taxonomy IDs (taxids) using the NCBI taxid file from: <ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/taxonomy/#">https://www.uniprot.org/taxonomy/#</ext-link> which contained 2,658,466 organism entries. Bacteria and viruses were extracted, and those with “No lineage” were removed. The bacteria and viruses were mapped to their corresponding KEGG infectious disease classification from <ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/brite/br08401">https://www.genome.jp/brite/br08401</ext-link>. If there were less than two <italic>homo sapiens</italic> proteins that interacted with a given pathogen, they were removed as a minimum of 2 proteins are required for the subsequent analysis. There were 312 viruses and 57 bacteria that remaining after filtration.</p>
    </sec>
    <sec id="Sec15">
      <title>Comorbidity predictions</title>
      <p id="Par35">Comorbidities were predicted by LeMeDISCO; we refer the reader to Ref.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> for details. Following determination of the significant comorbidities associated with the 312 viruses and 57 bacteria curated from HPIDB, a virus-disease network and a bacteria-disease network were constructed. Following determination of the significant comorbidities associated with the 312 viruses and 57 bacteria curated from HPIDB, a virus-disease network and a bacteria-disease network were constructed.</p>
    </sec>
    <sec id="Sec16">
      <title>Pan-virus and pan-bacteria assessment</title>
      <p id="Par36">We first assessed the frequency of each ICD-10 disease group across all the significant (q-value &lt; 0.05) comorbidities. Then, to find out which ICD-10 disease groups are affected most by pathogens, we define a relative risk (RR) of disease group after infection with respect to background (all possible source of causes):<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{RR}} = \frac{{{\raise0.7ex\hbox{${Number\;of\;comorbidities\;by\;group}$} \!\mathord{\left/ {\vphantom {{Number\;of\;comorbidities\;by\;group} {total\;number\;of\;comorbidities}}}\right.\kern-\nulldelimiterspace} \!\lower0.7ex\hbox{${total\;number\;of\;comorbidities}$}}}}{{{\raise0.7ex\hbox{${Number\;of\;diseases\;in\;the\;group}$} \!\mathord{\left/ {\vphantom {{Number\;of\;diseases\;in\;the\;group} {number\;of\;diseases\;in\;the\;library\left( { = 3608} \right) }}}\right.\kern-\nulldelimiterspace} \!\lower0.7ex\hbox{${number\;of\;diseases\;in\;the\;library\left( { = 3608} \right) }$}}}}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mtext>RR</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfrac bevelled="true"><mml:mrow><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.277778em"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.277778em"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.277778em"/><mml:mi>b</mml:mi><mml:mi>y</mml:mi><mml:mspace width="0.277778em"/><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.277778em"/><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.277778em"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.277778em"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mfrac bevelled="true"><mml:mrow><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.277778em"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.277778em"/><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.277778em"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.277778em"/><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.277778em"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.277778em"/><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.277778em"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.277778em"/><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>b</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>y</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mo>=</mml:mo><mml:mn>3608</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="41598_2022_25412_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par37">and calculate a corresponding <italic>p</italic> value using Fisher’s exact test<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>.</p>
    </sec>
    <sec id="Sec17">
      <title>Oncogenic/oncolytic index</title>
      <p id="Par38">For each pathogen an oncogenic/oncolytic index (onco_index) characterized by its <italic>p</italic> value was computed. The <italic>p</italic> value is calculated by Fisher’s exact test<sup><xref ref-type="bibr" rid="CR85">85</xref></sup> of the overlapped cancer drivers of the COSMIC 723 census proteins<sup><xref ref-type="bibr" rid="CR67">67</xref></sup> with the interactome proteins. The <italic>p</italic> value is calculated on the following contingency table:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\left( {\begin{array}{*{20}c} {N^{overlapped} } &amp; {N^{interatome} - N^{overlapped} } \\ {N^{driver} } &amp; {N^{total} - N^{driver} } \\ \end{array} } \right)$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mfenced close=")" open="("><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">overlapped</mml:mi></mml:mrow></mml:msup></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">interatome</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">overlapped</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">driver</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">driver</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="41598_2022_25412_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par39">Here <inline-formula id="IEq1"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}^{overlapped}$$\end{document}</tex-math><mml:math id="M6"><mml:msup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">overlapped</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq1.gif"/></alternatives></inline-formula> is the number of overlapped proteins between <inline-formula id="IEq2"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}^{interatome}$$\end{document}</tex-math><mml:math id="M8"><mml:msup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">interatome</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq2.gif"/></alternatives></inline-formula> of interactomes of the given pathogen and the <inline-formula id="IEq3"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}^{driver}$$\end{document}</tex-math><mml:math id="M10"><mml:msup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">driver</mml:mi></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq3.gif"/></alternatives></inline-formula> = 723 cancer drivers, <inline-formula id="IEq4"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}^{total}=\mathrm{18,663}$$\end{document}</tex-math><mml:math id="M12"><mml:mrow><mml:msup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">total</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mn>18</mml:mn><mml:mo>,</mml:mo><mml:mn>663</mml:mn></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq4.gif"/></alternatives></inline-formula> is the total number of human proteins considered in the work. Onco_MOA proteins are defined as those of the pathogen’s interactomes overlapped with the 723 drivers.</p>
    </sec>
    <sec id="Sec18">
      <title>Oncogenic/oncolytic distinguishing and propensity</title>
      <p id="Par40">To distinguish an oncolytic from oncogenic pathogen, we examine the possible difference between the interactomes (the human partner proteins a pathogen interacts with) of the oncogenic or oncolytic pathogens as evident from literature. We first collect all the interactomes of oncogenic or oncolytic pathogens and then count the frequencies that each human protein is part of the given pathogen-human interactome. Then, using the frequencies of these two lists, we calculate a <italic>p</italic> value<sup><xref ref-type="bibr" rid="CR85">85</xref></sup> of each protein T’s relative risk for oncolytic or oncogenic effects using the following contingency tables:<disp-formula id="Equ3"><label>3a</label><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\left( {\begin{array}{*{20}c} {N_{lytic}^{T} } &amp; {N_{lytic}^{all} - N_{lytic}^{T} } \\ {N_{genic}^{T} } &amp; {N_{genic}^{all} - N_{genic}^{T} } \\ \end{array} } \right)$$\end{document}</tex-math><mml:math id="M14" display="block"><mml:mfenced close=")" open="("><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">lytic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mtd><mml:mtd><mml:mrow><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">lytic</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">lytic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">genic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">genic</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">genic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="41598_2022_25412_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ4"><label>3b</label><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\left( {\begin{array}{*{20}c} {N_{genic}^{T} } &amp; {N_{genic}^{all} - N_{genic}^{T} } \\ {N_{lytic}^{T} } &amp; {N_{lytic}^{all} - N_{lytic}^{T} } \\ \end{array} } \right)$$\end{document}</tex-math><mml:math id="M16" display="block"><mml:mfenced close=")" open="("><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">genic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mtd><mml:mtd><mml:mrow><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">genic</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">genic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">lytic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">lytic</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">lytic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="41598_2022_25412_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula>where (<xref rid="Equ3" ref-type="">3a</xref>) for oncolytic effect, (<xref rid="Equ4" ref-type="">3b</xref>) for oncogenic effect; <inline-formula id="IEq5"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{lytic}^{T}$$\end{document}</tex-math><mml:math id="M18"><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">lytic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq5.gif"/></alternatives></inline-formula>,<inline-formula id="IEq6"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{genic}^{T}$$\end{document}</tex-math><mml:math id="M20"><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">genic</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq6.gif"/></alternatives></inline-formula> are numbers of oncolytic, oncogenic pathogens targeting the protein T; <inline-formula id="IEq7"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{lytic}^{all}$$\end{document}</tex-math><mml:math id="M22"><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">lytic</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq7.gif"/></alternatives></inline-formula>, <inline-formula id="IEq8"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{genic}^{all}$$\end{document}</tex-math><mml:math id="M24"><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">genic</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq8.gif"/></alternatives></inline-formula> are total number of oncolytic, oncogenic pathogens. We then define the oncolytic or oncogenic propensity of a pathogen as<disp-formula id="Equ5"><label>4</label><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{propensity}} = \mathop \sum \limits_{interactomes} - {\text{log}}\left( {p - value} \right)/N_{onco}^{all}$$\end{document}</tex-math><mml:math id="M26" display="block"><mml:mrow><mml:mtext>propensity</mml:mtext><mml:mo>=</mml:mo><mml:munder><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi mathvariant="italic">interactomes</mml:mi></mml:mrow></mml:munder><mml:mo>-</mml:mo><mml:mtext>log</mml:mtext><mml:mfenced close=")" open="("><mml:mrow><mml:mi>p</mml:mi><mml:mo>-</mml:mo><mml:mi>v</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mfenced><mml:mo stretchy="false">/</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">onco</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><graphic xlink:href="41598_2022_25412_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par41">The oncolytic propensity is obtained using the <italic>p</italic> value from (<xref rid="Equ3" ref-type="">3a</xref>) and <inline-formula id="IEq9"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{onco}^{all}$$\end{document}</tex-math><mml:math id="M28"><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">onco</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq9.gif"/></alternatives></inline-formula> is the total number of unique interactomes of oncolytic pathogens; and the oncogenic propensity from (<xref rid="Equ4" ref-type="">3b</xref>) and <inline-formula id="IEq10"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{onco}^{all}$$\end{document}</tex-math><mml:math id="M30"><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">onco</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">all</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="41598_2022_25412_Article_IEq10.gif"/></alternatives></inline-formula> is the total number of unique interactomes of oncogenic pathogens. When a pathogen’s oncolytic propensity &gt; oncogenic propensity, we predict it to be an oncolytic pathogen; otherwise it is classified as an oncogenic pathogen. Oncolytic_MOA proteins are defined as the overlap of interactomes of given pathogen with the union of those from literature supported oncolytic pathogens.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec19">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="41598_2022_25412_MOESM1_ESM.docx">
            <caption>
              <p>Supplementary Information 1.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="41598_2022_25412_MOESM2_ESM.xlsx">
            <caption>
              <p>Supplementary Information 2.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <sec>
    <title>Supplementary Information</title>
    <p>The online version contains supplementary material available at 10.1038/s41598-022-25412-x.</p>
  </sec>
  <ack>
    <title>Acknowledgements</title>
    <p>We thank Bartosz Ilkowski for internal computing support and Jessica Forness for proof-reading the manuscript.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>Conceptualization: J.S. Methodology: H.Z., C.A., J.S. Investigation: H.Z. Visualization: C.A. Funding acquisition: J.S. Project administration: J.S. Supervision: J.S. Writing—original draft: H.Z., C.A., J.S. Writing—subsequent drafts, review &amp; editing: H.Z., J.S., C.A.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This project was funded by R35GM118039 of the Division of General Medical Sciences of the NIH.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Data availability</title>
    <p>The datasets generated and/or analysed during the current study are not publicly available due to the tools generating them are independently licensed, but are available from the corresponding author on reasonable request.</p>
  </notes>
  <notes id="FPar1" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par42">The authors declare no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Piret</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Boivin</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Pandemics throughout history</article-title>
        <source>Front. Microbiol.</source>
        <year>2021</year>
        <pub-id pub-id-type="doi">10.3389/fmicb.2020.631736</pub-id>
        <?supplied-pmid 33584597?>
        <pub-id pub-id-type="pmid">33584597</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shaw-Taylor</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>An introduction to the history of infectious diseases, epidemics and the early phases of the long-run decline in mortality</article-title>
        <source>Econ Hist Rev</source>
        <year>2020</year>
        <volume>73</volume>
        <fpage>E1</fpage>
        <lpage>E19</lpage>
        <pub-id pub-id-type="doi">10.1111/ehr.13019</pub-id>
        <?supplied-pmid 32834070?>
        <pub-id pub-id-type="pmid">32834070</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cates</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lucero-Obusan</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dahl</surname>
            <given-names>RM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Risk for in-hospital complications associated with covid-19 and influenza—Veterans health administration, United States, October 1, 2018–May 31, 2020</article-title>
        <source>MMWR Morb. Mortal. Wkly. Rep.</source>
        <year>2020</year>
        <volume>2020</volume>
        <issue>69</issue>
        <fpage>1528</fpage>
        <lpage>1534</lpage>
        <pub-id pub-id-type="doi">10.15585/mmwr.mm6942e3</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Selwyn</surname>
            <given-names>PA</given-names>
          </name>
        </person-group>
        <article-title>Complications of HIV infection: A systems-based approach</article-title>
        <source>Am. Fam. Physician</source>
        <year>2011</year>
        <volume>83</volume>
        <fpage>395</fpage>
        <lpage>406</lpage>
        <?supplied-pmid 21322514?>
        <pub-id pub-id-type="pmid">21322514</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rothberg</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Haessler</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>RB</given-names>
          </name>
        </person-group>
        <article-title>Complications of viral influenza</article-title>
        <source>Am. J. Med.</source>
        <year>2008</year>
        <volume>121</volume>
        <fpage>258</fpage>
        <lpage>264</lpage>
        <pub-id pub-id-type="doi">10.1016/j.amjmed.2007.10.040</pub-id>
        <?supplied-pmid 18374680?>
        <pub-id pub-id-type="pmid">18374680</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Long</surname>
            <given-names>SS</given-names>
          </name>
        </person-group>
        <article-title>Neurologic complications of common respiratory tract virus infections</article-title>
        <source>J. Pediatr.</source>
        <year>2021</year>
        <volume>239</volume>
        <fpage>1</fpage>
        <lpage>4</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jpeds.2021.10.003</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hebsur</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vakil</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Oetgen</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>Lazarous</surname>
            <given-names>DF</given-names>
          </name>
        </person-group>
        <article-title>Influenza and coronary artery disease: Exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarction</article-title>
        <source>Rev. Cardiovasc. Med.</source>
        <year>2014</year>
        <volume>15</volume>
        <fpage>168</fpage>
        <lpage>175</lpage>
        <pub-id pub-id-type="doi">10.3909/ricm0692</pub-id>
        <?supplied-pmid 25051134?>
        <pub-id pub-id-type="pmid">25051134</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kwok</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Mentzer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Knight</surname>
            <given-names>JC</given-names>
          </name>
        </person-group>
        <article-title>Host genetics and infectious disease: New tools, insights and translational opportunities</article-title>
        <source>Nat. Rev. Genet.</source>
        <year>2021</year>
        <volume>22</volume>
        <fpage>137</fpage>
        <lpage>153</lpage>
        <pub-id pub-id-type="doi">10.1038/s41576-020-00297-6</pub-id>
        <?supplied-pmid 33277640?>
        <pub-id pub-id-type="pmid">33277640</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <mixed-citation publication-type="other">Gysi, D. M. <italic>et al.</italic> Network medicine framework for identifying drug repurposing opportunities for COVID-19. ArXiv <ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2004.07229">https://arxiv.org/abs/2004.07229</ext-link> (2020).</mixed-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kwiatkowski</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Susceptibility to infection</article-title>
        <source>BMJ</source>
        <year>2000</year>
        <volume>321</volume>
        <fpage>1061</fpage>
        <lpage>1065</lpage>
        <pub-id pub-id-type="doi">10.1136/bmj.321.7268.1061</pub-id>
        <?supplied-pmid 11053181?>
        <pub-id pub-id-type="pmid">11053181</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Abbott</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Are infections seeding some cases of Alzheimer’s disease?</article-title>
        <source>Nature</source>
        <year>2020</year>
        <volume>587</volume>
        <fpage>22</fpage>
        <lpage>25</lpage>
        <pub-id pub-id-type="doi">10.1038/d41586-020-03084-9</pub-id>
        <?supplied-pmid 33149296?>
        <pub-id pub-id-type="pmid">33149296</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Harley</surname>
            <given-names>JB</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity</article-title>
        <source>Nat. Genet.</source>
        <year>2018</year>
        <volume>50</volume>
        <fpage>699</fpage>
        <lpage>707</lpage>
        <pub-id pub-id-type="doi">10.1038/s41588-018-0102-3</pub-id>
        <?supplied-pmid 29662164?>
        <pub-id pub-id-type="pmid">29662164</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Alemany</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Viruses in cancer treatment</article-title>
        <source>Clin. Transl. Oncol.</source>
        <year>2013</year>
        <volume>15</volume>
        <fpage>182</fpage>
        <lpage>188</lpage>
        <pub-id pub-id-type="doi">10.1007/s12094-012-0951-7</pub-id>
        <?supplied-pmid 23143950?>
        <pub-id pub-id-type="pmid">23143950</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mui</surname>
            <given-names>UN</given-names>
          </name>
          <name>
            <surname>Haley</surname>
            <given-names>CT</given-names>
          </name>
          <name>
            <surname>Tyring</surname>
            <given-names>SK</given-names>
          </name>
        </person-group>
        <article-title>Viral oncology: Molecular biology and pathogenesis</article-title>
        <source>J. Clin. Med.</source>
        <year>2017</year>
        <volume>6</volume>
        <fpage>111</fpage>
        <pub-id pub-id-type="doi">10.3390/jcm6120111</pub-id>
        <?supplied-pmid 29186062?>
        <pub-id pub-id-type="pmid">29186062</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bouvard</surname>
            <given-names>V</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A review of human carcinogens–Part B: Biological agents</article-title>
        <source>Lancet Oncol.</source>
        <year>2009</year>
        <volume>10</volume>
        <fpage>321</fpage>
        <lpage>322</lpage>
        <pub-id pub-id-type="doi">10.1016/s1470-2045(09)70096-8</pub-id>
        <?supplied-pmid 19350698?>
        <pub-id pub-id-type="pmid">19350698</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Burd</surname>
            <given-names>EM</given-names>
          </name>
        </person-group>
        <article-title>Human papillomavirus and cervical cancer</article-title>
        <source>Clin. Microbiol. Rev.</source>
        <year>2003</year>
        <volume>16</volume>
        <fpage>1</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="doi">10.1128/cmr.16.1.1-17.2003</pub-id>
        <?supplied-pmid 12525422?>
        <pub-id pub-id-type="pmid">12525422</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stingi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cirillo</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>SARS-CoV-2 infection and cancer</article-title>
        <source>BioEssays</source>
        <year>2021</year>
        <volume>43</volume>
        <fpage>2000289</fpage>
        <pub-id pub-id-type="doi">10.1002/bies.202000289</pub-id>
        <?supplied-pmid 34081334?>
        <pub-id pub-id-type="pmid">34081334</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huo</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>H5N1 influenza a virus replicates productively in pancreatic cells and induces apoptosis and pro-inflammatory cytokine response</article-title>
        <source>Front. Cell Infect. Microbiol.</source>
        <year>2018</year>
        <volume>8</volume>
        <fpage>386</fpage>
        <pub-id pub-id-type="doi">10.3389/fcimb.2018.00386</pub-id>
        <?supplied-pmid 30460207?>
        <pub-id pub-id-type="pmid">30460207</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aref</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bailey</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Fielding</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Measles to the rescue: A review of oncolytic measles virus</article-title>
        <source>Viruses</source>
        <year>2016</year>
        <pub-id pub-id-type="doi">10.3390/v8100294</pub-id>
        <?supplied-pmid 27782084?>
        <pub-id pub-id-type="pmid">27782084</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Nemunaitis</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Herpes simplex virus 1 (HSV-1) for cancer treatment</article-title>
        <source>Cancer Gene Ther.</source>
        <year>2006</year>
        <volume>13</volume>
        <fpage>975</fpage>
        <lpage>992</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.cgt.7700946</pub-id>
        <?supplied-pmid 16604059?>
        <pub-id pub-id-type="pmid">16604059</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Astore</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ilkowski</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Forness</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Skolnick</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>LeMeDISCO is a computational method for large-scale prediction &amp; molecular interpretation of disease comorbidity</article-title>
        <source>Commun. Biol.</source>
        <year>2022</year>
        <volume>5</volume>
        <fpage>870</fpage>
        <pub-id pub-id-type="doi">10.1038/s42003-022-03816-9</pub-id>
        <?supplied-pmid 36008469?>
        <pub-id pub-id-type="pmid">36008469</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ammari</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Gresham</surname>
            <given-names>CR</given-names>
          </name>
          <name>
            <surname>McCarthy</surname>
            <given-names>FM</given-names>
          </name>
          <name>
            <surname>Nanduri</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>HPIDB 2.0: A curated database for host–pathogen interactions</article-title>
        <source>Database</source>
        <year>2016</year>
        <pub-id pub-id-type="doi">10.1093/database/baw103</pub-id>
        <?supplied-pmid 27374121?>
        <pub-id pub-id-type="pmid">27374121</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MEDICASCY: A machine learning approach for predicting small molecule drug side effects, indications, efficacy and mode of action</article-title>
        <source>Mol. Pharm.</source>
        <year>2020</year>
        <volume>17</volume>
        <fpage>1558</fpage>
        <lpage>1574</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b01248</pub-id>
        <?supplied-pmid 32237745?>
        <pub-id pub-id-type="pmid">32237745</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Menche</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Disease networks. Uncovering disease-disease relationships through the incomplete interactome</article-title>
        <source>Science</source>
        <year>2015</year>
        <volume>347</volume>
        <fpage>1257601</fpage>
        <pub-id pub-id-type="doi">10.1126/science.1257601</pub-id>
        <?supplied-pmid 25700523?>
        <pub-id pub-id-type="pmid">25700523</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ko</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Cho</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>J-S</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Identification of disease comorbidity through hidden molecular mechanisms</article-title>
        <source>Sci. Rep.</source>
        <year>2016</year>
        <volume>6</volume>
        <fpage>39433</fpage>
        <pub-id pub-id-type="doi">10.1038/srep39433</pub-id>
        <?supplied-pmid 27991583?>
        <pub-id pub-id-type="pmid">27991583</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Astore</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Jacob</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Skolnick</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Prediction of severe adverse events, modes of action and drug treatments for COVID-19’s complications</article-title>
        <source>Sci. Rep.</source>
        <year>2021</year>
        <volume>11</volume>
        <fpage>20864</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-021-00368-6</pub-id>
        <?supplied-pmid 34675303?>
        <pub-id pub-id-type="pmid">34675303</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wouk</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Rechenchoski</surname>
            <given-names>DZ</given-names>
          </name>
          <name>
            <surname>Rodrigues</surname>
            <given-names>BCD</given-names>
          </name>
          <name>
            <surname>Ribelato</surname>
            <given-names>EV</given-names>
          </name>
          <name>
            <surname>Faccin-Galhardi</surname>
            <given-names>LC</given-names>
          </name>
        </person-group>
        <article-title>Viral infections and their relationship to neurological disorders</article-title>
        <source>Arch. Virol.</source>
        <year>2021</year>
        <volume>166</volume>
        <fpage>733</fpage>
        <lpage>753</lpage>
        <pub-id pub-id-type="doi">10.1007/s00705-021-04959-6</pub-id>
        <?supplied-pmid 33502593?>
        <pub-id pub-id-type="pmid">33502593</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mattson</surname>
            <given-names>MP</given-names>
          </name>
        </person-group>
        <article-title>Infectious agents and age-related neurodegenerative disorders</article-title>
        <source>Ageing Res. Rev.</source>
        <year>2004</year>
        <volume>3</volume>
        <fpage>105</fpage>
        <lpage>120</lpage>
        <pub-id pub-id-type="doi">10.1016/j.arr.2003.08.005</pub-id>
        <?supplied-pmid 15163105?>
        <pub-id pub-id-type="pmid">15163105</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Smatti</surname>
            <given-names>MK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms</article-title>
        <source>Viruses</source>
        <year>2019</year>
        <volume>11</volume>
        <fpage>762</fpage>
        <pub-id pub-id-type="doi">10.3390/v11080762</pub-id>
        <?supplied-pmid 31430946?>
        <pub-id pub-id-type="pmid">31430946</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fernández-Real</surname>
            <given-names>J-M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Burden of infection and insulin resistance in healthy middle-aged men</article-title>
        <source>Diabetes Care</source>
        <year>2006</year>
        <volume>29</volume>
        <fpage>1058</fpage>
        <pub-id pub-id-type="doi">10.2337/dc05-2068</pub-id>
        <?supplied-pmid 16644637?>
        <pub-id pub-id-type="pmid">16644637</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hernandez-Romieu</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Garg</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rosenberg</surname>
            <given-names>ES</given-names>
          </name>
          <name>
            <surname>Thompson-Paul</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Skarbinski</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009–2010</article-title>
        <source>BMJ Open Diabetes Res. Care</source>
        <year>2017</year>
        <volume>5</volume>
        <fpage>e000304</fpage>
        <pub-id pub-id-type="doi">10.1136/bmjdrc-2016-000304</pub-id>
        <?supplied-pmid 28191320?>
        <pub-id pub-id-type="pmid">28191320</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fujiya</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Fulminant type 1 diabetes mellitus associated with a reactivation of Epstein-Barr virus that developed in the course of chemotherapy of multiple myeloma</article-title>
        <source>J. Diabetes Investig.</source>
        <year>2010</year>
        <volume>1</volume>
        <fpage>286</fpage>
        <lpage>289</lpage>
        <pub-id pub-id-type="doi">10.1111/j.2040-1124.2010.00061.x</pub-id>
        <?supplied-pmid 24843446?>
        <pub-id pub-id-type="pmid">24843446</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schaffert</surname>
            <given-names>CS</given-names>
          </name>
        </person-group>
        <article-title>Role of MGST1 in reactive intermediate-induced injury</article-title>
        <source>World J. Gastroenterol.</source>
        <year>2011</year>
        <volume>17</volume>
        <fpage>2552</fpage>
        <lpage>2557</lpage>
        <pub-id pub-id-type="doi">10.3748/wjg.v17.i20.2552</pub-id>
        <?supplied-pmid 21633660?>
        <pub-id pub-id-type="pmid">21633660</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cathepsin B contributes to autophagy-related 7 (Atg7)-induced nod-like receptor 3 (NLRP3)-dependent proinflammatory response and aggravates lipotoxicity in rat insulinoma cell line</article-title>
        <source>J. Biol. Chem.</source>
        <year>2013</year>
        <volume>288</volume>
        <fpage>30094</fpage>
        <lpage>30104</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M113.494286</pub-id>
        <?supplied-pmid 23986436?>
        <pub-id pub-id-type="pmid">23986436</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>DeFronzo</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009</article-title>
        <source>Diabetologia</source>
        <year>2010</year>
        <volume>53</volume>
        <fpage>1270</fpage>
        <lpage>1287</lpage>
        <pub-id pub-id-type="doi">10.1007/s00125-010-1684-1</pub-id>
        <?supplied-pmid 20361178?>
        <pub-id pub-id-type="pmid">20361178</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study</article-title>
        <source>PLoS ONE</source>
        <year>2018</year>
        <volume>13</volume>
        <fpage>e0193646</fpage>
        <lpage>e0193646</lpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0193646</pub-id>
        <?supplied-pmid 29499055?>
        <pub-id pub-id-type="pmid">29499055</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tonhajzerova</surname>
            <given-names>I</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Novel biomarkers of early atherosclerotic changes for personalised prevention of cardiovascular disease in cervical cancer and human papillomavirus infection</article-title>
        <source>Int. J. Mol. Sci.</source>
        <year>2019</year>
        <volume>20</volume>
        <fpage>3720</fpage>
        <pub-id pub-id-type="doi">10.3390/ijms20153720</pub-id>
        <?supplied-pmid 31366035?>
        <pub-id pub-id-type="pmid">31366035</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Adinolfi</surname>
            <given-names>LE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms</article-title>
        <source>World J. Gastroenterol.</source>
        <year>2014</year>
        <volume>20</volume>
        <fpage>3410</fpage>
        <lpage>3417</lpage>
        <pub-id pub-id-type="doi">10.3748/wjg.v20.i13.3410</pub-id>
        <?supplied-pmid 24707124?>
        <pub-id pub-id-type="pmid">24707124</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mao</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Shan</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Identification of key genes and miRNAs associated with carotid atherosclerosis based on mRNA-seq data</article-title>
        <source>Medicine</source>
        <year>2018</year>
        <volume>97</volume>
        <fpage>e9832</fpage>
        <pub-id pub-id-type="doi">10.1097/md.0000000000009832</pub-id>
        <?supplied-pmid 29595698?>
        <pub-id pub-id-type="pmid">29595698</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Swidsinski</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mucosal flora in inflammatory bowel disease</article-title>
        <source>Gastroenterology</source>
        <year>2002</year>
        <volume>122</volume>
        <fpage>44</fpage>
        <lpage>54</lpage>
        <pub-id pub-id-type="doi">10.1053/gast.2002.30294</pub-id>
        <?supplied-pmid 11781279?>
        <pub-id pub-id-type="pmid">11781279</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>I</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Alteration of gut microbiota in inflammatory bowel disease (IBD): Cause or consequence? IBD treatment targeting the gut microbiome</article-title>
        <source>Pathogens</source>
        <year>2019</year>
        <volume>8</volume>
        <fpage>126</fpage>
        <pub-id pub-id-type="doi">10.3390/pathogens8030126</pub-id>
        <?supplied-pmid 31412603?>
        <pub-id pub-id-type="pmid">31412603</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ramos</surname>
            <given-names>GP</given-names>
          </name>
          <name>
            <surname>Papadakis</surname>
            <given-names>KA</given-names>
          </name>
        </person-group>
        <article-title>Mechanisms of disease: Inflammatory bowel diseases</article-title>
        <source>Mayo Clin. Proc.</source>
        <year>2019</year>
        <volume>94</volume>
        <fpage>155</fpage>
        <lpage>165</lpage>
        <pub-id pub-id-type="doi">10.1016/j.mayocp.2018.09.013</pub-id>
        <?supplied-pmid 30611442?>
        <pub-id pub-id-type="pmid">30611442</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Maddika</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>791 morbidity and mortality of influenza virus in inflammatory bowel disease</article-title>
        <source>Off. J. Am. Coll. Gastroenterol. ACG</source>
        <year>2019</year>
        <volume>114</volume>
        <fpage>S458</fpage>
        <pub-id pub-id-type="doi">10.14309/01.ajg.0000592700.13392.68</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lautenbach</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Lichtenstein</surname>
            <given-names>GR</given-names>
          </name>
        </person-group>
        <article-title>Human immunodeficiency virus infection and Crohn's disease: the role of the CD4 cell in inflammatory bowel disease</article-title>
        <source>J. Clin. Gastroenterol.</source>
        <year>1997</year>
        <volume>25</volume>
        <fpage>456</fpage>
        <lpage>459</lpage>
        <pub-id pub-id-type="doi">10.1097/00004836-199709000-00013</pub-id>
        <?supplied-pmid 9412950?>
        <pub-id pub-id-type="pmid">9412950</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dotan</surname>
            <given-names>I</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies</article-title>
        <source>Med. Res. Rev.</source>
        <year>2020</year>
        <volume>40</volume>
        <fpage>245</fpage>
        <lpage>262</lpage>
        <pub-id pub-id-type="doi">10.1002/med.21601</pub-id>
        <?supplied-pmid 31215680?>
        <pub-id pub-id-type="pmid">31215680</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Maeda</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gelsolin as a potential biomarker for endoscopic activity and mucosal healing in ulcerative colitis</article-title>
        <source>Biomedicines</source>
        <year>2022</year>
        <volume>10</volume>
        <fpage>872</fpage>
        <pub-id pub-id-type="doi">10.3390/biomedicines10040872</pub-id>
        <?supplied-pmid 35453622?>
        <pub-id pub-id-type="pmid">35453622</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fan</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>New insights into the pathogenesis of Alzheimer's disease</article-title>
        <source>Front. Neurol.</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.3389/fneur.2019.01312</pub-id>
        <?supplied-pmid 33569032?>
        <pub-id pub-id-type="pmid">33569032</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Amran</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Influenza vaccination is associated with a reduced incidence of Alzheimer’s disease</article-title>
        <source>Alzheimer’s Dement.</source>
        <year>2020</year>
        <volume>16</volume>
        <fpage>e041693</fpage>
        <pub-id pub-id-type="doi">10.1002/alz.041693</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Blair</surname>
            <given-names>LJ</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Sabbagh</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Dickey</surname>
            <given-names>CA</given-names>
          </name>
        </person-group>
        <article-title>The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease</article-title>
        <source>J. Neurochem.</source>
        <year>2015</year>
        <volume>133</volume>
        <fpage>1</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.1111/jnc.13033</pub-id>
        <?supplied-pmid 25628064?>
        <pub-id pub-id-type="pmid">25628064</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dave</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Identification of retinoblastoma binding protein 7 (Rbbp7) as a mediator against tau acetylation and subsequent neuronal loss in Alzheimer's disease and related tauopathies</article-title>
        <source>Acta Neuropathol.</source>
        <year>2021</year>
        <volume>142</volume>
        <fpage>279</fpage>
        <lpage>294</lpage>
        <pub-id pub-id-type="doi">10.1007/s00401-021-02323-1</pub-id>
        <?supplied-pmid 33978814?>
        <pub-id pub-id-type="pmid">33978814</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Park</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>Hallows</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Chakrabarty</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Davies</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Vincent</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice</article-title>
        <source>J. Neurosci.</source>
        <year>2007</year>
        <volume>27</volume>
        <fpage>2969</fpage>
        <lpage>2978</lpage>
        <pub-id pub-id-type="doi">10.1523/jneurosci.0186-07.2007</pub-id>
        <?supplied-pmid 17360920?>
        <pub-id pub-id-type="pmid">17360920</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>FBXW11 deletion alleviates Alzheimer's disease by reducing neuroinflammation and amyloid-β plaque formation via repression of ASK1 signaling</article-title>
        <source>Biochem. Biophys. Res. Commun.</source>
        <year>2021</year>
        <volume>548</volume>
        <fpage>104</fpage>
        <lpage>111</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.12.081</pub-id>
        <?supplied-pmid 33640602?>
        <pub-id pub-id-type="pmid">33640602</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Henkel</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Offor</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Fisher</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>The role of infections and leukocytes in male infertility</article-title>
        <source>Andrologia</source>
        <year>2021</year>
        <volume>53</volume>
        <fpage>e13743</fpage>
        <pub-id pub-id-type="doi">10.1111/and.13743</pub-id>
        <?supplied-pmid 32693434?>
        <pub-id pub-id-type="pmid">32693434</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Andersson</surname>
            <given-names>SA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Reduced insulin secretion correlates with decreased expression of exocytotic genes in pancreatic islets from patients with type 2 diabetes</article-title>
        <source>Mol. Cell. Endocrinol.</source>
        <year>2012</year>
        <volume>364</volume>
        <fpage>36</fpage>
        <lpage>45</lpage>
        <pub-id pub-id-type="doi">10.1016/j.mce.2012.08.009</pub-id>
        <?supplied-pmid 22939844?>
        <pub-id pub-id-type="pmid">22939844</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>West</surname>
            <given-names>NA</given-names>
          </name>
          <name>
            <surname>Kechris</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Dabelea</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Exposure to maternal diabetes in utero and DNA methylation patterns in the offspring</article-title>
        <source>Immunometabolism</source>
        <year>2013</year>
        <volume>1</volume>
        <fpage>1</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.2478/immun-2013-0001</pub-id>
        <?supplied-pmid 23741625?>
        <pub-id pub-id-type="pmid">23741625</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>S-S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated multi-omics analysis reveals the effect of maternal gestational diabetes on fetal mouse hippocampi</article-title>
        <source>Front. Cell Dev. Biol.</source>
        <year>2022</year>
        <pub-id pub-id-type="doi">10.3389/fcell.2022.748862</pub-id>
        <?supplied-pmid 36438554?>
        <pub-id pub-id-type="pmid">36438554</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Louis</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Agarwal</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mondal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Talukdar</surname>
            <given-names>I</given-names>
          </name>
        </person-group>
        <article-title>A global analysis on the differential regulation of RNA binding proteins (RBPs) by TNF–α as potential modulators of metabolic syndromes</article-title>
        <source>BBA Adv.</source>
        <year>2022</year>
        <volume>2</volume>
        <fpage>100037</fpage>
        <pub-id pub-id-type="doi">10.1016/j.bbadva.2021.100037</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Alanis-Lobato</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Andrade-Navarro</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Schaefer</surname>
            <given-names>MH</given-names>
          </name>
        </person-group>
        <article-title>HIPPIE v2.0: Enhancing meaningfulness and reliability of protein–protein interaction networks</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2016</year>
        <volume>45</volume>
        <fpage>D408</fpage>
        <lpage>D414</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkw985</pub-id>
        <?supplied-pmid 27794551?>
        <pub-id pub-id-type="pmid">27794551</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jassal</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The reactome pathway knowledgebase</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2020</year>
        <volume>48</volume>
        <fpage>D498</fpage>
        <lpage>d503</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkz1031</pub-id>
        <?supplied-pmid 31691815?>
        <pub-id pub-id-type="pmid">31691815</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jansen</surname>
            <given-names>AJG</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity</article-title>
        <source>Blood Adv.</source>
        <year>2020</year>
        <volume>4</volume>
        <fpage>2967</fpage>
        <lpage>2978</lpage>
        <pub-id pub-id-type="doi">10.1182/bloodadvances.2020001640</pub-id>
        <?supplied-pmid 32609845?>
        <pub-id pub-id-type="pmid">32609845</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yamamoto</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Influenza vaccination-associated acute thrombocytopenia and diffuse alveolar hemorrhage</article-title>
        <source>Intern. Med.</source>
        <year>2020</year>
        <volume>59</volume>
        <fpage>1633</fpage>
        <lpage>1637</lpage>
        <pub-id pub-id-type="doi">10.2169/internalmedicine.3991-19</pub-id>
        <?supplied-pmid 32188805?>
        <pub-id pub-id-type="pmid">32188805</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dusek</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Severity of experimental autoimmune uveitis is reduced by pretreatment with live probiotic <italic>Escherichia coli</italic> Nissle 1917</article-title>
        <source>Cells</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.3390/cells10010023</pub-id>
        <?supplied-pmid 33375578?>
        <pub-id pub-id-type="pmid">33375578</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ghavami</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Alpha-1-antitrypsin phenotypes and HLA-B27 typing in uveitis patients in southeast Iran</article-title>
        <source>Clin. Biochem.</source>
        <year>2005</year>
        <volume>38</volume>
        <fpage>425</fpage>
        <lpage>432</lpage>
        <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2005.02.006</pub-id>
        <?supplied-pmid 15820772?>
        <pub-id pub-id-type="pmid">15820772</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Clark</surname>
            <given-names>WF</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: A prospective cohort study</article-title>
        <source>BMJ</source>
        <year>2010</year>
        <volume>341</volume>
        <fpage>c6020</fpage>
        <pub-id pub-id-type="doi">10.1136/bmj.c6020</pub-id>
        <?supplied-pmid 21084368?>
        <pub-id pub-id-type="pmid">21084368</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Venturini</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tamaro</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Monti-Bragadin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Carlassare</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Mutagenicity in Salmonella typhimurium of some angelicin derivatives proposed as new monofunctional agents for the photochemotherapy of psoriasis</article-title>
        <source>Mutat. Res.</source>
        <year>1981</year>
        <volume>88</volume>
        <fpage>17</fpage>
        <lpage>22</lpage>
        <pub-id pub-id-type="doi">10.1016/0165-1218(81)90085-9</pub-id>
        <?supplied-pmid 7010144?>
        <pub-id pub-id-type="pmid">7010144</pub-id>
      </element-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zong</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Suo</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title><italic>Salmonella</italic> infection causes hyperglycemia for decreased GLP-1 content by Enteroendocrine L cells pyroptosis in pigs</article-title>
        <source>Int. J. Mol. Sci.</source>
        <year>2022</year>
        <pub-id pub-id-type="doi">10.3390/ijms23031272</pub-id>
        <?supplied-pmid 36361664?>
        <pub-id pub-id-type="pmid">36361664</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tate</surname>
            <given-names>JG</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>COSMIC: The catalogue of somatic mutations in cancer</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2019</year>
        <volume>47</volume>
        <fpage>D941</fpage>
        <lpage>D947</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id>
        <?supplied-pmid 30371878?>
        <pub-id pub-id-type="pmid">30371878</pub-id>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pagano</surname>
            <given-names>JS</given-names>
          </name>
        </person-group>
        <article-title>Epstein-Barr virus: The first human tumor virus and its role in cancer</article-title>
        <source>Proc. Assoc. Am. Physicians</source>
        <year>1999</year>
        <volume>111</volume>
        <fpage>573</fpage>
        <lpage>580</lpage>
        <pub-id pub-id-type="doi">10.1046/j.1525-1381.1999.t01-1-99220.x</pub-id>
        <?supplied-pmid 10591086?>
        <pub-id pub-id-type="pmid">10591086</pub-id>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mitsudomi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Yatabe</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer</article-title>
        <source>Febs J.</source>
        <year>2010</year>
        <volume>277</volume>
        <fpage>301</fpage>
        <lpage>308</lpage>
        <pub-id pub-id-type="doi">10.1111/j.1742-4658.2009.07448.x</pub-id>
        <?supplied-pmid 19922469?>
        <pub-id pub-id-type="pmid">19922469</pub-id>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gordon</surname>
            <given-names>DE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title>
        <source>Nature</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1038/s41586-41020-42286-41589</pub-id>
        <?supplied-pmid 33116285?>
        <pub-id pub-id-type="pmid">33116285</pub-id>
      </element-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yasuda</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Human NINEIN polymorphism at codon 1111 is associated with the risk of colorectal cancer</article-title>
        <source>Biomed. Rep.</source>
        <year>2020</year>
        <volume>13</volume>
        <fpage>45</fpage>
        <pub-id pub-id-type="doi">10.3892/br.2020.1352</pub-id>
        <?supplied-pmid 32934817?>
        <pub-id pub-id-type="pmid">32934817</pub-id>
      </element-citation>
    </ref>
    <ref id="CR72">
      <label>72.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>El Messaoudi-Aubert</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Role for the MOV10 RNA helicase in polycomb-mediated repression of the INK4a tumor suppressor</article-title>
        <source>Nat. Struct. Mol. Biol.</source>
        <year>2010</year>
        <volume>17</volume>
        <fpage>862</fpage>
        <lpage>868</lpage>
        <pub-id pub-id-type="doi">10.1038/nsmb.1824</pub-id>
        <?supplied-pmid 20543829?>
        <pub-id pub-id-type="pmid">20543829</pub-id>
      </element-citation>
    </ref>
    <ref id="CR73">
      <label>73.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bhattacharjya</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Inhibition of nucleoporin member Nup214 expression by miR-133b perturbs mitotic timing and leads to cell death</article-title>
        <source>Mol. Cancer</source>
        <year>2015</year>
        <volume>14</volume>
        <fpage>42</fpage>
        <pub-id pub-id-type="doi">10.1186/s12943-015-0299-z</pub-id>
        <?supplied-pmid 25743594?>
        <pub-id pub-id-type="pmid">25743594</pub-id>
      </element-citation>
    </ref>
    <ref id="CR74">
      <label>74.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cytoplasmic poly(A) binding protein 4 is highly expressed in human colorectal cancer and correlates with better prognosis</article-title>
        <source>J. Genet. Genom.</source>
        <year>2012</year>
        <volume>39</volume>
        <fpage>369</fpage>
        <lpage>374</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jgg.2012.05.007</pub-id>
      </element-citation>
    </ref>
    <ref id="CR75">
      <label>75.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors</article-title>
        <source>Sci. Rep.</source>
        <year>2022</year>
        <volume>12</volume>
        <fpage>5924</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-022-09889-0</pub-id>
        <?supplied-pmid 35395865?>
        <pub-id pub-id-type="pmid">35395865</pub-id>
      </element-citation>
    </ref>
    <ref id="CR76">
      <label>76.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Samuels</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Waldman</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Oncogenic mutations of PIK3CA in human cancers</article-title>
        <source>Curr. Top. Microbiol. Immunol.</source>
        <year>2010</year>
        <volume>347</volume>
        <fpage>21</fpage>
        <lpage>41</lpage>
        <pub-id pub-id-type="doi">10.1007/82_2010_68</pub-id>
        <?supplied-pmid 20535651?>
        <pub-id pub-id-type="pmid">20535651</pub-id>
      </element-citation>
    </ref>
    <ref id="CR77">
      <label>77.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kwong</surname>
            <given-names>JC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Acute myocardial infarction after laboratory-confirmed influenza infection</article-title>
        <source>N. Engl. J. Med.</source>
        <year>2018</year>
        <volume>378</volume>
        <fpage>345</fpage>
        <lpage>353</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa1702090</pub-id>
        <?supplied-pmid 29365305?>
        <pub-id pub-id-type="pmid">29365305</pub-id>
      </element-citation>
    </ref>
    <ref id="CR78">
      <label>78.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chow</surname>
            <given-names>EJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Acute cardiovascular events associated with influenza in hospitalized adults</article-title>
        <source>Ann. Intern. Med.</source>
        <year>2020</year>
        <volume>173</volume>
        <fpage>605</fpage>
        <lpage>613</lpage>
        <pub-id pub-id-type="doi">10.7326/M20-1509</pub-id>
        <?supplied-pmid 32833488?>
        <pub-id pub-id-type="pmid">32833488</pub-id>
      </element-citation>
    </ref>
    <ref id="CR79">
      <label>79.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Honorat</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Influenza A(H1N1)-associated ischemic stroke in a 9-month-old child</article-title>
        <source>Pediatr. Emerg. Care</source>
        <year>2012</year>
        <volume>28</volume>
        <fpage>368</fpage>
        <lpage>369</lpage>
        <pub-id pub-id-type="doi">10.1097/PEC.0b013e31824dcaa4</pub-id>
        <?supplied-pmid 22472654?>
        <pub-id pub-id-type="pmid">22472654</pub-id>
      </element-citation>
    </ref>
    <ref id="CR80">
      <label>80.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oudit</surname>
            <given-names>GY</given-names>
          </name>
          <name>
            <surname>Penninger</surname>
            <given-names>JM</given-names>
          </name>
        </person-group>
        <article-title>Cardiac regulation by phosphoinositide 3-kinases and PTEN</article-title>
        <source>Cardiovasc. Res.</source>
        <year>2009</year>
        <volume>82</volume>
        <fpage>250</fpage>
        <lpage>260</lpage>
        <pub-id pub-id-type="doi">10.1093/cvr/cvp014</pub-id>
        <?supplied-pmid 19147653?>
        <pub-id pub-id-type="pmid">19147653</pub-id>
      </element-citation>
    </ref>
    <ref id="CR81">
      <label>81.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Patel</surname>
            <given-names>VB</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PI3Kα-regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease</article-title>
        <source>Nat. Commun.</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>5390</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-07812-8</pub-id>
        <?supplied-pmid 30568254?>
        <pub-id pub-id-type="pmid">30568254</pub-id>
      </element-citation>
    </ref>
    <ref id="CR82">
      <label>82.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zeitz</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Smyth</surname>
            <given-names>JW</given-names>
          </name>
        </person-group>
        <article-title>Translating translation to mechanisms of cardiac hypertrophy</article-title>
        <source>J. Cardiovasc. Dev. Dis.</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.3390/jcdd7010009</pub-id>
        <?supplied-pmid 32164190?>
        <pub-id pub-id-type="pmid">32164190</pub-id>
      </element-citation>
    </ref>
    <ref id="CR83">
      <label>83.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Mitochondrial protein translation: Emerging roles and clinical significance in disease</article-title>
        <source>Front. Cell Dev. Biol.</source>
        <year>2021</year>
        <pub-id pub-id-type="doi">10.3389/fcell.2021.675465</pub-id>
        <?supplied-pmid 35860598?>
        <pub-id pub-id-type="pmid">35860598</pub-id>
      </element-citation>
    </ref>
    <ref id="CR84">
      <label>84.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Casad</surname>
            <given-names>ME</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cardiomyopathy is associated with ribosomal protein gene haplo-insufficiency in Drosophila melanogaster</article-title>
        <source>Genetics</source>
        <year>2011</year>
        <volume>189</volume>
        <fpage>861</fpage>
        <lpage>870</lpage>
        <pub-id pub-id-type="doi">10.1534/genetics.111.131482</pub-id>
        <?supplied-pmid 21890737?>
        <pub-id pub-id-type="pmid">21890737</pub-id>
      </element-citation>
    </ref>
    <ref id="CR85">
      <label>85.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fisher</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>On the interpretation of χ<sup>2</sup> from contingency tables, and the calculation of P</article-title>
        <source>J. R. Stat. Soc.</source>
        <year>1922</year>
        <volume>85</volume>
        <fpage>87</fpage>
        <lpage>94</lpage>
        <pub-id pub-id-type="doi">10.2307/2340521</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
